| 1 | Prostatectomy in patients with bleeding disorders. (Kirby K, Mesrobian HG, Fried F) J Urol 1988 Jul;140(1):87-90 5 Citations |
| 1 | Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. (Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SR) Int J Radiat Oncol Biol Phys 1991 Sep;21(4):935-9 373 Citations |
| 1 | Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? (Lawton CA, Cox JD, Glisch C, Murray KJ, Byhardt RW, Wilson JF) Cancer 1992 Jun 01;69(11):2761-6 35 Citations |
| 1 | Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? (Zincke H) Cancer 1992 Dec 01;70(11):2742-3 1 Citation |
| 1 | Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. (Langenstroer P, Tang R, Shapiro E, Divish B, Opgenorth T, Lepor H) J Urol 1993 Aug;150(2 Pt 1):495-9 116 Citations |
| 1 | Binding and functional properties of endothelin receptor subtypes in the human prostate. (Kobayashi S, Tang R, Wang B, Opgenorth T, Langenstroer P, Shapiro E, Lepor H) Mol Pharmacol 1994 Feb;45(2):306-11 67 Citations |
| 1 | Prostate cancer: are racial differences in clinical stage and survival explained by differences in symptoms? (Lawton CA, Cantrell JE, Derus SW, Murray KJ, Byhardt RW, Wilson JF) Radiology 1994 Jul;192(1):37-40 10 Citations |
| 1 | An outcome study of patient-controlled morphine analgesia, with or without ketorolac, following radical retropubic prostatectomy. (See WA, Fuller JR, Toner ML) J Urol 1995 Oct;154(4):1429-32 25 Citations |
| 1 | Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. (Lyon PB, See WA, Xu Y, Cohen MB) Prostate 1995 Oct;27(4):179-86 29 Citations |
| 2 | Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. (Schapira MM, McAuliffe TL, Nattinger AB) Med Care 1995 Nov;33(11):1079-88 65 Citations |
| 1 | RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. (Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, Beard C, Cella D) Int J Radiat Oncol Biol Phys 1995 Nov 01;33(4):901-6 68 Citations |
| 1 | Association between prostate cancer in black Americans and an allele of the PADPRP pseudogene locus on chromosome 13. (Doll JA, Suarez BK, Donis-Keller H) Am J Hum Genet 1996 Feb;58(2):425-8 10 Citations |
| 1 | Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. (See WA, Dreicer R, Wheeler JA, Forest PK, Loening S) Cancer 1996 Mar 01;77(5):924-7 5 Citations |
| 1 | Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. (Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z) Int J Cancer 1996 May 16;66(4):515-9 90 Citations |
| 1 | A change in practice: current urologic practice in response to reports concerning vasectomy and prostate cancer. (Sandlow JI, Kreder KJ) Fertil Steril 1996 Aug;66(2):281-4 12 Citations |
| 1 | Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). (Lawton CA, Coleman CN, Buzydlowski JW, Forman JD, Marcial VA, DelRowe JD, Rotman M) Int J Radiat Oncol Biol Phys 1996 Oct 01;36(3):673-80 18 Citations |
| 1 | A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. (Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WA) Cancer Invest 1997;15(4):311-7 22 Citations |
| 1 | Laparoscopic pelvic lymph node dissection following definitive radiotherapy for carcinoma of the prostate. (Lund GO, Winfield HN, Donovan JF, See WA, Loening SA, Williams RD) J Urol 1997 Feb;157(2):548-51 8 Citations |
| 1 | Enhanced decision-making: the use of a videotape decision-aid for patients with prostate cancer. (Schapira MM, Meade C, Nattinger AB) Patient Educ Couns 1997 Feb;30(2):119-27 63 Citations |
| 1 | Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. (Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D) J Clin Oncol 1997 Mar;15(3):1013-21 583 Citations |
| 1 | Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. (Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV) Int J Radiat Oncol Biol Phys 1997 Jul 15;38(5):931-9 74 Citations |
| 1 | Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. (Griebling TL, Ozkutlu D, See WA, Cohen MB) Mod Pathol 1997 Aug;10(8):804-9 55 Citations |
| 1 | Disease-free and overall survival after cryosurgical monotherapy for clinical stages B and C carcinoma of the prostate: a 20-year followup. (Porter MP, Ahaghotu CA, Loening SA, See WA) J Urol 1997 Oct;158(4):1466-9 17 Citations |
| 1 | Prostate cancer: A challenge for screening. (Donnell RF) Surg Oncol Clin N Am 1999 Oct;8(4):693-702, vii 3 Citations |
| 1 | Information sources and professional consultations sought by men newly diagnosed as having prostate cancer (Schapira MM, Meade CD, McAuliffe TL, Lawrence WF, Nattinger AB) Journal of Cancer Education December 1999;14(4):243-247 9 Citations |
| 1 | Information sources and professional consultations sought by men newly diagnosed as having prostate cancer () Journal of Cancer Education December 1999;14(4):243-247 |
| 1 | The effect of an illustrated pamphlet decision-aid on the use of prostate cancer screening tests. (Schapira MM, VanRuiswyk J) J Fam Pract 2000 May;49(5):418-24 108 Citations |
| 1 | Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. (Roach M 3RD, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W, Cox J) Int J Radiat Oncol Biol Phys 2000 Jun 01;47(3):617-27 180 Citations |
| 1 | Biomarker distribution after injection into the canine prostate: implications for gene therapy. (Siemens DR, Iwasawa T, Austin JC, Williams RD, See WA, Hedican SP, Tartaglia J, Flynn CM, Cohen MB, Rodgers J, Ratliff TL) BJU Int 2000 Dec;86(9):1076-83 4 Citations |
| 1 | The bicalutamide Early Prostate Cancer Program. Demography. (See WA, McLeod D, Iversen P, Wirth M) Urol Oncol 2001 Mar;6(2):43-47 |
| 2 | Effect of treatment on quality of life among men with clinically localized prostate cancer. (Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB) Med Care 2001 Mar;39(3):243-53 80 Citations |
| 1 | Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. (Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):947-56 103 Citations |
| 1 | Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. (Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):937-46 374 Citations |
| 1 | Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. (Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D) Int J Radiat Oncol Biol Phys 2001 Aug 01;50(5):1243-52 763 Citations |
| 1 | Phase II trial of GM-CSF in advanced prostate cancer. (Dreicer R, See WA, Klein EA) Invest New Drugs 2001;19(3):261-5 35 Citations |
| 1 | Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. (Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP) Prostate 2001 Dec 01;49(4):293-305 128 Citations |
| 1 | Optimized intensity-modulated arc therapy for prostate cancer treatment. (Ma L, Yu CX, Earl M, Holmes T, Sarfaraz M, Li XA, Shepard D, Amin P, DiBiase S, Suntharalingam M, Mansfield C) Int J Cancer 2001 Dec 20;96(6):379-84 44 Citations |
| 1 | Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. (See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ, Casodex Early Prostate Cancer Trialist Group) J Urol 2002 Aug;168(2):429-35 214 Citations |
| 1 | Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. (Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M) Int J Radiat Oncol Biol Phys 2002 Dec 01;54(5):1302-10 61 Citations |
| 1 | How low is the alpha/beta ratio for prostate cancer? (Wang JZ, Guerrero M, Li XA) Int J Radiat Oncol Biol Phys 2003 Jan 01;55(1):194-203 306 Citations |
| 1 | Case selection and outcome of radical perineal prostatectomy in localized prostate cancer (Holzbeierlein JM, Langenstroer P, Porter HJ, Thrasher JB) International Braz J Urol July/August 2003;29(4):291-299 12 Citations |
| 1 | Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. (Wang JZ, Li XA) Med Phys 2003 Jan;30(1):34-40 57 Citations |
| 1 | Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. (Pollack A, Grignon DJ, Heydon KH, Hammond EH, Lawton CA, Mesic JB, Fu KK, Porter AT, Abrams RA, Shipley WU) J Clin Oncol 2003 Apr 01;21(7):1238-48 31 Citations |
| 1 | Determination of cyclooxygenase and arachidonic acid metabolites in invasive human prostate cancer cells. (Nithipatikom K, Borscheid CL, Kajdacsy-Balla A, Kaul S, Lindholm PF, Pytynia KB, Campbell WB) Adv Exp Med Biol 2002;507:269-74 4 Citations |
| 1 | Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate. (Lawton CA) Semin Radiat Oncol 2003 Apr;13(2):141-51 9 Citations |
| 1 | Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. (Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE) Nat Med 2003 Jun;9(6):774-80 278 Citations |
| 1 | Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. (Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS, Radiation Therapy Oncology Group 9413) J Clin Oncol 2003 May 15;21(10):1904-11 619 Citations |
| 1 | Variability of the International Prostate Symptom Score in men with lower urinary tract symptoms. (O'Connor RC, Bales GT, Avila D, Gerber GS) Scand J Urol Nephrol 2003;37(1):35-7 17 Citations |
| 1 | Urethral stents in benign prostate hyperplasia. (Donnell RF) Curr Urol Rep 2003 Aug;4(4):282-6 4 Citations |
| 1 | Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer. (See WA) Curr Treat Options Oncol 2003 Oct;4(5):351-62 6 Citations |
| 1 | Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. (Li XA, Wang JZ, Stewart RD, DiBiase SJ) Phys Med Biol 2003 Sep 07;48(17):2753-65 46 Citations |
| 1 | Low α/β ratio for prostate cancer: In response to Dr. Fowler et al. [3] (multiple letter) (Wang JZ, Guerrero M, Li XA) International Journal of Radiation Oncology Biology Physics 1 October 2003;57(2):595-596 15 Citations |
| 1 | The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? (Wang JZ, Li XA, Yu CX, DiBiase SJ) Int J Radiat Oncol Biol Phys 2003 Nov 15;57(4):1101-8 107 Citations |
| 1 | Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. (Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU, Radiation Therapy Oncology Group) J Clin Oncol 2003 Nov 01;21(21):3972-8 688 Citations |
| 1 | Pigment epithelium-derived factor, a human testis epididymis secretory product, promotes human prostate stromal cell growth in culture. (Grayhack JT, Smith ND, Ilio K, Wambi C, Kasjanski R, Crawford SE, Doll JA, Wang Z, Lee C, Kozlowski JM) J Urol 2004 Jan;171(1):434-8 9 Citations |
| 1 | Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. (Ruiz-Llorente L, Ortega-Gutiérrez S, Viso A, Sánchez MG, Sánchez AM, Fernández C, Ramos JA, Hillard C, Lasunción MA, López-Rodríguez ML, Díaz-Laviada I) Br J Pharmacol 2004 Feb;141(3):457-67 39 Citations |
| 1 | Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. (Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group) Urology 2004 May;63(5):928-33 16 Citations |
| 1 | Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. (Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM) J Clin Oncol 2004 Jun 01;22(11):2133-40 147 Citations |
| 1 | Epidemiology of inflammation and prostate cancer. (Donnell RF) Curr Urol Rep 2004 Aug;5(4):297 |
| 1 | Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. (Halin S, Wikström P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE, Bergh A) Cancer Res 2004 Aug 15;64(16):5664-71 78 Citations |
| 1 | Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium. (Schlicht M, Matysiak B, Brodzeller T, Wen X, Liu H, Zhou G, Dhir R, Hessner MJ, Tonellato P, Suckow M, Pollard M, Datta MW) BMC Genomics 2004 Aug 20;5(1):58 28 Citations |
| 1 | Serum prostate-specific antigen concentration is increased in acromegalic women. (Manetti L, Lupi I, Genovesi M, Morselli L, Grasso L, Nencetti C, Gasperi M, Bogazzi F, Bartalena L, Martino E) J Endocrinol Invest 2004;27(7):643-7 3 Citations |
| 1 | Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. (Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group) J Urol 2004 Nov;172(5 Pt 1):1865-70 201 Citations |
| 1 | Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. (Carlson DJ, Stewart RD, Li XA, Jennings K, Wang JZ, Guerrero M) Phys Med Biol 2004 Oct 07;49(19):4477-91 100 Citations |
| 2 | 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. (Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB) Cancer Res 2004 Dec 15;64(24):8826-30 131 Citations |
| 1 | MO‐D‐T‐6E‐06: In Vitro Measurement of the Repair Time for Prostate Cancer (Wang J, Rhee J, Stewart R, li X) Medical Physics June 2005;32(6):2062 1 Citation |
| 1 | Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31 (Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D, Carroll PR) Urologic Oncology Seminars and Original Investigations November/December 2005;23(6):462-463 1 Citation |
| 1 | Modeling prostate cancer: in regards to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401). (Wang JZ, Mayr NA, Li XA, Stewart RD) Int J Radiat Oncol Biol Phys 2005 Jan 01;61(1):309-10; author reply 310-1 4 Citations |
| 1 | Early release of the neurovascular bundles and optical loupe magnification lead to improved and earlier return of potency following radical retropubic prostatectomy. (Chuang MS, O'Connor RC, Laven BA, Orvieto MA, Brendler CB) J Urol 2005 Feb;173(2):537-9 31 Citations |
| 1 | Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. (Lawton CA, Winter K, Grignon D, Pilepich MV) J Clin Oncol 2005 Feb 01;23(4):800-7 161 Citations |
| 1 | The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. (Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S) Prostate Cancer Prostatic Dis 2005;8(1):22-30 122 Citations |
| 1 | HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. (Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE) Oncogene 2005 Apr 28;24(19):3110-20 357 Citations |
| 1 | Case selection and outcome of radical perineal prostatectomy in localized prostate cancer. (Holzbeierlein JM, Langenstroer P, Porter HJ 2nd, Thrasher JB) Int Braz J Urol 2003;29(4):291-9 |
| 2 | Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. (Li XA, Wang JZ, Jursinic PA, Lawton CA, Wang D) Int J Radiat Oncol Biol Phys 2005 Mar 15;61(4):1251-7 62 Citations |
| 1 | Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. (Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D) Int J Radiat Oncol Biol Phys 2005 Apr 01;61(5):1285-90 859 Citations |
| 1 | Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. (Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M 3rd, Gore EM, Tepper JE) Int J Radiat Oncol Biol Phys 2005 May 01;62(1):3-19 59 Citations |
| 1 | A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. (Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB) Biochem Biophys Res Commun 2005 Jul 15;332(4):1028-33 50 Citations |
| 1 | Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database. (Langenstroer P, Carroll P, Thrasher JB) J Urol 2005 Jul;174(1):118-20 5 Citations |
| 1 | Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. (Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H) Int J Radiat Oncol Biol Phys 2005 Jul 15;62(4):956-64 55 Citations |
| 1 | Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. (Langenstroer P, Kramer B, Cutting B, Amling C, Poultan T, Lance R, Thrasher JB) J Urol 2005 Aug;174(2):642-5 28 Citations |
| 1 | H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. (Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA) Int J Cancer 2006 Jan 01;118(1):62-73 78 Citations |
| 1 | Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. (Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ) J Urol 2005 Oct;174(4 Pt 1):1262-5 26 Citations |
| 1 | Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. (Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C, 'Casodex' Early Prostate Cancer Trialists Group) Radiother Oncol 2005 Jul;76(1):4-10 62 Citations |
| 1 | Complications after cystectomy and urinary diversion in patients previously treated for localized prostate cancer. (Tolhurst SR, Rapp DE, O'Connor RC, Lyon MB, Orvieto MA, Steinberg GD) Urology 2005 Oct;66(4):824-9 30 Citations |
| 1 | Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? (Stadler WM, Michaelis LC, Ratain MJ) J Clin Oncol 2005 Nov 01;23(31):8124-5; author reply 8125-6 2 Citations |
| 2 | A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. (Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H) Int J Radiat Oncol Biol Phys 2006 Mar 01;64(3):804-9 34 Citations |
| 1 | A population model of prostate cancer incidence. (Tsodikov A, Szabo A, Wegelin J) Stat Med 2006 Aug 30;25(16):2846-66 43 Citations |
| 1 | Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. (Shipley WU, Desilvio M, Pilepich MV, Roach M 3rd, Wolkov HB, Sause WT, Rubin P, Lawton CA) Int J Radiat Oncol Biol Phys 2006 Mar 15;64(4):1162-7 48 Citations |
| 1 | Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. (McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group) BJU Int 2006 Feb;97(2):247-54 256 Citations |
| 3 | Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity. (Huh J, Liepins A, Zielonka J, Andrekopoulos C, Kalyanaraman B, Sorokin A) Cancer Res 2006 Apr 01;66(7):3726-36 59 Citations |
| 1 | The effects of the exaggerated lithotomy position for radical perineal prostatectomy on respiratory mechanics. (Choi SJ, Gwak MS, Ko JS, Lee H, Yang M, Lee SM, Kim GS, Kim MH) Anaesthesia 2006 May;61(5):439-43 24 Citations |
| 1 | Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? (Warren KS, Chodak GW, See WA, Iverson P, McLeod D, Wirth M, Morris C, Armstrong J) J Urol 2006 Jul;176(1):70-3; discussion 73-4 12 Citations |
| 1 | The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. (McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J) J Urol 2006 Jul;176(1):75-80 42 Citations |
| 2 | Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. (Gillin MT, Dunning BF, Lawton CA, Foley WD, Byhardt RW, Morton G, Baikadi M, Pisansky TT, Michalski JM, Ibbott G, Lopez F, Radiation Therapy Oncology Group) Brachytherapy 2006;5(3):152-6 4 Citations |
| 1 | Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data. (Wang JZ, Li XA, Mayr NA) Br J Radiol 2006 Nov;79(947):905-11 38 Citations |
| 1 | Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. (Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD) Cancer Res 2006 Aug 01;66(15):7509-15 138 Citations |
| 1 | The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. (See WA, Tyrrell CJ, CASODEX Early Prostate Cancer Trialists' Group) J Cancer Res Clin Oncol 2006 Aug;132 Suppl 1(Suppl 1):S7-16 57 Citations |
| 1 | Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link? (Atallah E, Schiffer CA) Leuk Res 2007 May;31(5):720-1 2 Citations |
| 1 | Bicalutamide adjuvant to radical prostatectomy. (See WA) Rev Urol 2004;6 Suppl 2(Suppl 2):S20-8 |
| 1 | Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. (Roach M 3rd, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR Jr, Shipley WU) Int J Radiat Oncol Biol Phys 2006 Nov 01;66(3):647-53 174 Citations |
| 1 | Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. (Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC) Cancer 2006 Nov 15;107(10):2392-400 59 Citations |
| 1 | Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). (Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H) Int J Radiat Oncol Biol Phys 2007 Jan 01;67(1):39-47 47 Citations |
| 2 | SU‐FF‐J‐45: A Comparison of Daily Megavoltage CT and Ultrasound Imaging Guided Radiation Therapy for Prostate Cancer (Peng C, Kainz K, Lawton C, li X) Medical Physics June 2007;34(6):2378 |
| 1 | Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. (Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ, Medin JA) FASEB J 2007 Mar;21(3):754-65 53 Citations |
| 1 | A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. (Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M) Cancer 2007 Feb 15;109(4):802-10 233 Citations |
| 2 | Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data. (Smither AR, Guralnick ML, Davis NB, See WA) BMC Urol 2007 Feb 05;7:2 75 Citations |
| 1 | Localised and Locally Advanced Prostate Cancer: Who to Treat and How? (Gillatt D, Klotz L, Lawton C, Miller K, Payne H) European Urology Supplements March 2007;6(3):334-343 1 Citation |
| 1 | Treatment Options in Prostate Cancer Once Primary Therapy Fails (Keane T, Gillatt D, Lawton C, Payne H, Tombal B) European Urology Supplements March 2007;6(3):344-353 4 Citations |
| 2 | Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. (Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H) Cancer 2007 Apr 15;109(8):1506-12 60 Citations |
| 1 | Intrahepatic portal hypertension secondary to metastatic carcinoma of the prostate. (Attila T, Datta MW, Sudakoff G, Abu-Hajir M, Massey BT) WMJ 2007 Feb;106(1):34-6 6 Citations |
| 1 | Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. (Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR, Campbell WB, Nithipatikom K) Int J Cancer 2007 Sep 01;121(5):984-91 47 Citations |
| 1 | Rectourethral fistula after combination radiotherapy for prostate cancer. (Marguet C, Raj GV, Brashears JH, Anscher MS, Ludwig K, Mouraviev V, Robertson CN, Polascik TJ) Urology 2007 May;69(5):898-901 51 Citations |
| 1 | An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. (Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr) Int J Radiat Oncol Biol Phys 2007 Nov 01;69(3):646-55 423 Citations |
| 1 | Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. (Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ) BJU Int 2007 Jul;100(1):70-5 53 Citations |
| 1 | Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. (Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T) Prostate Cancer Prostatic Dis 2008;11(1):46-52 8 Citations |
| 1 | In vivo MRI volumetric measurement of prostate regression and growth in mice. (Nastiuk KL, Liu H, Hamamura M, Muftuler LT, Nalcioglu O, Krolewski JJ) BMC Urol 2007 Jul 24;7:12 25 Citations |
| 1 | B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. (Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED) Cancer Res 2007 Aug 15;67(16):7893-900 239 Citations |
| 1 | Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. (Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W) Int J Radiat Oncol Biol Phys 2008 Feb 01;70(2):437-41 71 Citations |
| 1 | Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. (Bylow K, Mohile SG, Stadler WM, Dale W) Cancer 2007 Dec 15;110(12):2604-13 113 Citations |
| 1 | Quantifying the role of PSA screening in the US prostate cancer mortality decline. (Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E) Cancer Causes Control 2008 Mar;19(2):175-81 375 Citations |
| 2 | Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. (Li XA, Wang JZ, Stewart RD, Dibiase SJ, Wang D, Lawton CA) Br J Radiol 2008 Jan;81(961):59-68 10 Citations |
| 1 | Pelvic lymph node irradiation for prostate cancer: who, why, and when? (Wang D, Lawton C) Semin Radiat Oncol 2008 Jan;18(1):35-40 18 Citations |
| 1 | SU‐GG‐J‐155: Quantifying Interfractional Prostate Motion and Deformation Based On Daily KVCT to Determine Selection Criteria for Adaptive Correction Schemes (Peng C, Ahunbay E, li X) Medical Physics June 2008;35(6):2715 |
| 1 | WE‐C‐AUD B‐08: Biologically Based Corrections for Interfraction Variations During Prostate Cancer Radiation Therapy (Park JH, li XA, Godley A, Stewart RD) Medical Physics June 2008;35(6):2934 |
| 2 | WE‐E‐AUD C‐02: Impact of Image Quality On CT Guided Prostate Radiotherapy (Morrow N, Lawton C, li X) Medical Physics June 2008;35(6):2955 2 Citations |
| 1 | Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. (Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV) J Clin Oncol 2008 Feb 01;26(4):585-91 583 Citations |
| 2 | Long-term follow-up of single versus double cuff artificial urinary sphincter insertion for the treatment of severe postprostatectomy stress urinary incontinence. (O'Connor RC, Lyon MB, Guralnick ML, Bales GT) Urology 2008 Jan;71(1):90-3 109 Citations |
| 1 | Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. (Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU) J Clin Oncol 2008 May 20;26(15):2497-504 612 Citations |
| 1 | In vitro determination of radiation sensitivity parameters for DU-145 prostate cancer cells. (Wang JZ, Rhee JG, Shi P, Stewart RD, Allen Li X) Int J Radiat Biol 2008 Jun;84(6):515-22 11 Citations |
| 1 | Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. (Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M, Mohile SG) Urology 2008 Aug;72(2):422-7 142 Citations |
| 2 | Expression and function of fatty acid amide hydrolase in prostate cancer. (Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K) Int J Cancer 2008 Sep 15;123(6):1318-26 87 Citations |
| 1 | Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. (Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM) Mod Pathol 2008 Sep;21(9):1156-67 375 Citations |
| 1 | Roles of Eicosanoids in Prostate Cancer. (Nithipatikom K, Campbell WB) Future Lipidol 2008 Aug 01;3(4):453-467 17 Citations |
| 1 | Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. (Symes JC, Kurin M, Fleshner NE, Medin JA) Mol Cancer Ther 2008 Sep;7(9):3018-28 22 Citations |
| 1 | Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. (Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M 3rd, Pisansky TM, Seider M) Int J Radiat Oncol Biol Phys 2009 Jun 01;74(2):377-82 62 Citations |
| 1 | RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. (Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M) Int J Radiat Oncol Biol Phys 2009 Jun 01;74(2):383-7 370 Citations |
| 2 | SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells. (Zhi H, Yang XJ, Kuhnmuench J, Berg T, Thill R, Yang H, See WA, Becker CG, Williams CL, Li R) J Pathol 2009 Feb;217(3):389-97 22 Citations |
| 1 | DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. (Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG) Cancer Res 2008 Nov 01;68(21):8954-67 263 Citations |
| 1 | Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. (Bass R, Perry B, Langenstroer P, Thrasher JB, Dennis KL, Tawfik O, Holzbeierlein J) J Urol 2009 Feb;181(2):615-9; discussion 619-20 24 Citations |
| 1 | Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. (Symes JC, Siatskas C, Fowler DH, Medin JA) Cancer Gene Ther 2009 May;16(5):439-52 8 Citations |
| 2 | SU‐FF‐J‐132: Calculation of Cumulative Dose for Daily CT‐Guided Prostate Irradiation Using Deformable Image Registration (Godley A, Ahunbay E, Lawton C, li X) Medical Physics June 2009;36(6):2507 1 Citation |
| 3 | SU‐FF‐T‐79: Dosimetric QA Tests of An Online Replanning Technique for Prostate Adaptive Radiotherapy (Peng C, Ahunbay E, Chen G, Lawton C, li X) Medical Physics June 2009;36(6):2537 1 Citation |
| 3 | A comparison of daily megavoltage CT and ultrasound image guided radiation therapy for prostate cancer. (Peng C, Kainz K, Lawton C, Li XA) Med Phys 2008 Dec;35(12):5619-28 25 Citations |
| 1 | Hypofractionation for prostate cancer. (Ritter M, Forman J, Kupelian P, Lawton C, Petereit D) Cancer J 2009;15(1):1-6 67 Citations |
| 1 | Recutting prostate needle core biopsies with high grade prostatic intraepithelial neoplasia increases detection of adenocarcinoma. (Rapp DE, Msezane LP, Reynolds WS, Lotan TL, Obara P, O'Connor RC, Taxy JB, Gerber GS, Zagaja GP) Can J Urol 2009 Feb;16(1):4484-9 6 Citations |
| 1 | Multidimensional protein identification technology analysis highlights mitoxantrone-induced expression modulations in the primary prostate cancer cell proteome. (Symes J, Evangelou A, Ignatchenko A, Fleshner N, Kislinger T, Medin JA) Proteomics Clin Appl 2009 Mar;3(3):347-58 |
| 1 | Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. (Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM) J Clin Oncol 2009 Apr 01;27(10):1557-63 51 Citations |
| 1 | Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. (Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ) Clin Cancer Res 2009 Mar 15;15(6):2174-80 78 Citations |
| 1 | ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. (Michalski JM, Roach M 3rd, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR) Int J Radiat Oncol Biol Phys 2009 Jul 01;74(3):667-72 16 Citations |
| 1 | Bladder neck contracture after radical retropubic prostatectomy using an intussuscepted vesico-urethral anastomosis: incidence with long-term follow-up. (Garg T, See WA) BJU Int 2009 Oct;104(7):925-8 12 Citations |
| 1 | Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. (Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Ménard C) Int J Radiat Oncol Biol Phys 2010 Feb 01;76(2):361-8 361 Citations |
| 1 | Using QRRO survey data to assess compliance with quality indicators for breast and prostate cancer. (Owen JB, White JR, Zelefsky MJ, Wilson JF) J Am Coll Radiol 2009 Jun;6(6):442-7 18 Citations |
| 2 | Automated registration of large deformations for adaptive radiation therapy of prostate cancer. (Godley A, Ahunbay E, Peng C, Li XA) Med Phys 2009 Apr;36(4):1433-41 54 Citations |
| 1 | A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. (Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R) Invest New Drugs 2010 Oct;28(5):634-40 33 Citations |
| 1 | Laparoscopic mesh herniorrhaphy: impact on outcomes associated with radical retropubic prostatectomy. (Neff DA, See WA) Urol Oncol 2011;29(1):66-9 6 Citations |
| 1 | A structured implicit abstraction method to evaluate whether content of counseling before prostate cancer screening is consistent with recommendations by experts. (Farrell MH, Chan EC, Ladouceur LK, Stein JM) Patient Educ Couns 2009 Dec;77(3):322-7 4 Citations |
| 2 | SU‐GG‐T‐29: Dosimetric Advantages of Online Adaptive Replanning for Radiotherapy of the Prostate and Seminal Vesicles (Holmes S, Peng C, Ahunbay E, Lawton C, Wang D, li X) Medical Physics June 2010;37(6):3190 2 Citations |
| 1 | Characterization of soy-based changes in Wnt-frizzled signaling in prostate cancer (Liss MA, Schlicht M, Kahler A, Fitzgerald R, Thomassi T, Degueme A, Hessner M, Datta MW) Cancer Genomics and Proteomics September-October 2010;7(5):245-252 22 Citations |
| 1 | Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. (Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group) BJU Int 2010 Apr;105(8):1074-81 98 Citations |
| 1 | Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. (Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikström P, Bergh A) Neoplasia 2010 Apr;12(4):336-45 42 Citations |
| 3 | Online adaptive replanning method for prostate radiotherapy. (Ahunbay EE, Peng C, Holmes S, Godley A, Lawton C, Li XA) Int J Radiat Oncol Biol Phys 2010 Aug 01;77(5):1561-72 86 Citations |
| 1 | Prostate localization on daily cone-beam computed tomography images: accuracy assessment of similarity metrics. (Kim J, Hammoud R, Pradhan D, Zhong H, Jin RY, Movsas B, Chetty IJ) Int J Radiat Oncol Biol Phys 2010 Jul 15;77(4):1257-65 14 Citations |
| 1 | Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. (Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H) Int J Radiat Oncol Biol Phys 2010 Dec 01;78(5):1314-22 17 Citations |
| 1 | How can rates of prostate-specific antigen screening be reduced in men aged 80 and older? (Whittle J, Zablocki CJ) J Am Geriatr Soc 2010 Apr;58(4):757-9 8 Citations |
| 1 | Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. (Fitchev PP, Wcislak SM, Lee C, Bergh A, Brendler CB, Stellmach VM, Crawford SE, Mavroudis CD, Cornwell ML, Doll JA) Lab Invest 2010 Jul;90(7):1078-90 24 Citations |
| 1 | Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer (Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, Stadler WM) Journal of Geriatric Oncology June 2010;1(1):13-19 3 Citations |
| 1 | Use of cross species genomic profiling identifies pathways and genes differentially regulated in prostate cancer cells treated with soy protein isolates or purified genistein. (Liss MA, Schlicht M, Degueme A, Hessner M, Datta MW) Cancer Genomics Proteomics 2010;7(3):111-28 5 Citations |
| 1 | Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. (Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ) Int J Radiat Oncol Biol Phys 2011 Apr 01;79(5):1343-9 32 Citations |
| 1 | Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. (Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H) Int J Radiat Oncol Biol Phys 2011 Jun 01;80(2):445-52 14 Citations |
| 1 | Re: Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes: W. T. Lowrance, E. B. Elkin, L. M. Jacks, D. S. Yee, T. L. Jang, V. P. Laudone, B. D. Guillonneau, P. T. Scardino and J. A. Eastham J Urol 2010; 183: 1366-1372. (See WA) J Urol 2010 Oct;184(4):1573-4; author reply 1574 |
| 4 | Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. (Peng C, Ahunbay E, Chen G, Anderson S, Lawton C, Li XA) Int J Radiat Oncol Biol Phys 2011 Mar 01;79(3):909-14 70 Citations |
| 1 | Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. (Kerns SL, Ostrer H, Stock R, Li W, Moore J, Pearlman A, Campbell C, Shao Y, Stone N, Kusnetz L, Rosenstein BS) Int J Radiat Oncol Biol Phys 2010 Dec 01;78(5):1292-300 134 Citations |
| 1 | Characterization of soy-based changes in Wnt-frizzled signaling in prostate cancer. (Liss MA, Schlicht M, Kahler A, Fitzgerald R, Thomassi T, Degueme A, Hessner M, Datta MW) Cancer Genomics Proteomics 2010;7(5):245-52 |
| 1 | Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor. (Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Brendler CB, Lee C) Urology 2010 Dec;76(6):1519.e8-13 29 Citations |
| 1 | Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. (Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ) BJU Int 2011 Jul;108(2 Pt 2):E51-8 18 Citations |
| 1 | Benign prostate hyperplasia: a review of the year's progress from bench to clinic. (Donnell RF) Curr Opin Urol 2011 Jan;21(1):22-6 64 Citations |
| 1 | Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. (Nithipatikom K, Isbell MA, Endsley MP, Woodliff JE, Campbell WB) Prostaglandins Other Lipid Mediat 2011 Feb;94(1-2):34-43 43 Citations |
| 1 | SU‐E‐T‐780: Evaluation of Margin‐Reduction Using a Framework for Image‐Guided Adaptive Radiotherapy (IGART) of Prostate Cancer in the Clinical Setting () Medical Physics June 2011;38(6):3670 |
| 4 | TH‐C‐BRA‐04: Online Adaptive Radiotherapy for Prostate Cancer: Clinical Implementation and Initial Experience (li XA, Ahunbay E, Peng C, Chen G, Liu F, Lawton C) Medical Physics June 2011;38(6):3852-3853 |
| 3 | SU‐E‐T‐647: Quality of Prostate IMRT Plans Generated Using Biological versus Dose‐Volume Constraints () Medical Physics June 2011;38(6):3638 |
| 1 | Prostate Cancer (Michalski J, Pisansky TM, Lawton CA, Potters L, Kuban DA) Clinical Radiation Oncology Third Edition 1 January 2011:1037-1097 1 Citation |
| 1 | Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. (Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W) Urology 2011 Apr;77(4):934-40 60 Citations |
| 2 | Muscle endurance, cancer-related fatigue, and radiotherapy in prostate cancer survivors. (Alt CA, Gore EM, Montagnini ML, Ng AV) Muscle Nerve 2011 Mar;43(3):415-24 14 Citations |
| 1 | Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. (Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H) Int J Radiat Oncol Biol Phys 2011 Dec 01;81(5):1293-301 43 Citations |
| 1 | Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). (Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H) Int J Radiat Oncol Biol Phys 2011 Sep 01;81(1):1-7 34 Citations |
| 4 | Validation of an online replanning technique for prostate adaptive radiotherapy. (Peng C, Chen G, Ahunbay E, Wang D, Lawton C, Li XA) Phys Med Biol 2011 Jun 21;56(12):3659-68 21 Citations |
| 3 | The association of robotic surgical technology and hospital prostatectomy volumes: increasing market share through the adoption of technology. (Neuner JM, See WA, Pezzin LE, Tarima S, Nattinger AB) Cancer 2012 Jan 15;118(2):371-7 43 Citations |
| 1 | The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. (Hong SK, Kim JH, Lin MF, Park JI) Exp Cell Res 2011 Nov 01;317(18):2671-82 38 Citations |
| 1 | Prostate Cancer (Michalski JM, Pisansky TM, Lawton CA, Potters L, Kuban DA) Clinical Radiation Oncology Third Edition October 27, 2011:e51.1-e51.85 |
| 3 | Specific heat capacity of freshly excised prostate specimens. (Patch SK, Rao N, Kelly H, Jacobsohn K, See WA) Physiol Meas 2011 Nov;32(11):N55-64 10 Citations |
| 2 | Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. (Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB) Endocrinology 2012 Jan;153(1):29-41 34 Citations |
| 1 | Prostate Cancer (Michalski J, Pisansky TM, Lawton CA, Potters L, Kuban DA) Clinical Radiation Oncology Third Edition 2012:1037-1097 2 Citations |
| 1 | Radiation Therapy Oncology Group (RTOG) 9413: Randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) and neoadjuvant hormone therapy (NHT) to adjuvant hormone therapy (AHT). (Roach M, Yan Y, Lawton CA, Hsu IJ, Lustig RA, Jones CU, Rotman M, Zeitzer KL, Werner-Wasik M, Kim H, Thomas CR, Shipley WU, Sandler HM) J Clin Oncol 2012 Feb 10;30(5_suppl):96 |
| 2 | Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. (Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H) Int J Radiat Oncol Biol Phys 2012 Apr 01;82(5):e795-801 55 Citations |
| 1 | Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. (Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe JO, Lance RS, Troyer DA, Alessandro R, Semmes OJ, Kislinger T, Drake RR, Medin JA) J Proteome Res 2012 Apr 06;11(4):2386-96 70 Citations |
| 1 | Words of wisdom. Re: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. (See WA) Eur Urol 2012 May;61(5):1066 |
| 1 | Erratum: Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells (Endocrinology (2012) 153 (29-41)) (Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB) Endocrinology May 2012;153(5):2531 |
| 2 | Accumulating daily-varied dose distributions of prostate radiation therapy with soft-tissue-based kV CT guidance. (Godley A, Ahunbay E, Peng C, Li XA) J Appl Clin Med Phys 2012 May 10;13(3):3859 19 Citations |
| 2 | SU-E-T-579: Dosimetric Benefits of Online Adaptive Replanning for Post-Operative Radiation Therapy of Prostate Bed. (Liu F, Ahunbay E, Lawton C, Li X) Med Phys 2012 Jun;39(6Part19):3839 |
| 4 | SU-E-J-11: Characterization of Interfractioanal Anatomical Variations in Post-Operative Radiation Therapy for Prostate Bed. (Liu F, Ahunbay E, Christian R, Lawton C, Wang D, Li X) Med Phys 2012 Jun;39(6Part6):3654 |
| 1 | Epidural anesthesia and non-invasive ventilation for radical retropubic prostatectomy in two obese patients with chronic obstructive pulmonary disease. (Alonso-Iñigo JM, Herranz-Gordo A, Fas MJ, Giner R, Llopis JE) Rev Esp Anestesiol Reanim 2012 Dec;59(10):573-6 8 Citations |
| 1 | SU-E-T-579: Dosimetric Benefits of Online Adaptive Replanning for Post-Operative Radiation Therapy of Prostate Bed. (Liu F, Ahunbay E, Lawton C, Li X) Med Phys 2012 Jun;39(6):3839 |
| 1 | SU-E-J-11: Characterization of Interfractioanal Anatomical Variations in Post-Operative Radiation Therapy for Prostate Bed. (Liu F, Ahunbay E, Christian R, Lawton C, Wang D, Li X) Med Phys 2012 Jun;39(6):3654 |
| 1 | Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. (Ulmer WD, Prasad SM, Kowalczyk KJ, Gu X, Dodgion C, Lipsitz S, Palapattu GS, Choueiri TK, Hu JC) J Urol 2012 Sep;188(3):775-80 21 Citations |
| 1 | Results from the Quality Research in Radiation Oncology (QRRO) survey: Evaluation of dosimetric outcomes for low-dose-rate prostate brachytherapy. (Zelefsky MJ, Cohen GN, Bosch WR, Morikawa L, Khalid N, Crozier CL, Lee WR, Zietman A, Owen J, Wilson JF, Devlin PM) Brachytherapy 2013;12(1):19-24 2 Citations |
| 1 | Evaluation of the deformation and corresponding dosimetric implications in prostate cancer treatment. (Wen N, Glide-Hurst C, Nurushev T, Xing L, Kim J, Zhong H, Liu D, Liu M, Burmeister J, Movsas B, Chetty IJ) Phys Med Biol 2012 Sep 07;57(17):5361-79 39 Citations |
| 1 | An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer (Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M) Journal of Men S Health September 2012;9(3):182-189 1 Citation |
| 1 | An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. (Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M) J Mens Health 2012 Sep 01;9(3):182-189 1 Citation |
| 1 | Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. (Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR, Kislinger T) Mol Cell Proteomics 2012 Dec;11(12):1870-84 82 Citations |
| 1 | A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. (Kerns SL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, Rath L, De Ruysscher D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein BS) Int J Radiat Oncol Biol Phys 2013 Jan 01;85(1):e21-8 55 Citations |
| 1 | Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma. (Buckstein M, Kerns S, Forysthe K, Stone NN, Stock RG) BJU Int 2013 Mar;111(3 Pt B):E43-7 9 Citations |
| 1 | Stratification of postprostatectomy urinary function using expanded prostate cancer index composite. (Ellison JS, He C, Wood DP) Urology 2013 Jan;81(1):56-60 22 Citations |
| 1 | Diffusion-weighted magnetic resonance imaging of the prostate: improved robustness with stretched exponential modeling. (Mazaheri Y, Afaq A, Rowe DB, Lu Y, Shukla-Dave A, Grover J) J Comput Assist Tomogr 2012;36(6):695-703 61 Citations |
| 1 | National Radiation Oncology Registry: The pilot prostate cancer registry. (Nassif D, Chen RC, Hoffman KE, Kuban DA, Lawton CA, Michalski JM, Potters L, Rose CM, Sandler HM, Suh W, Wall T, Zietman AL, Bekelman JE) J Clin Oncol 2012 Dec;30(34_suppl):267 |
| 1 | Treatment efficiency of volumetric modulated arc therapy in comparison with intensity-modulated radiotherapy in the treatment of prostate cancer. (Hall WA, Fox TH, Jiang X, Prabhu RS, Rossi PJ, Godette K, Jani AB) J Am Coll Radiol 2013 Feb;10(2):128-34 19 Citations |
| 1 | Place of residence and primary treatment of prostate cancer: examining trends in rural and nonrural areas in Wisconsin. (Cetnar JP, Hampton JM, Williamson AA, Downs T, Wang D, Owen JB, Crouse B, Jones N, Wilson JF, Trentham-Dietz A) Urology 2013 Mar;81(3):540-6 16 Citations |
| 1 | Case series analysis of post-brachytherapy prostate edema and its relevance to post-implant dosimetry. Post-implant prostate edema and dosimetry. (Tejwani A, Bieniek E, Puckett L, Lavaf A, Guirguis A, Bennish A, Ashamalla H) J Contemp Brachytherapy 2012 Jun;4(2):75-80 11 Citations |
| 1 | A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. (Kerns SL, Stone NN, Stock RG, Rath L, Ostrer H, Rosenstein BS) J Urol 2013 Jul;190(1):102-8 52 Citations |
| 1 | Visualizing the prostate gland by MR imaging in young and old mice. (Ravoori M, Duggal J, Gagea M, Han L, Singh S, Liu P, Wei W, Ragan DK, Bankson JA, Ma J, Kundra V) PLoS One 2013;8(3):e55746 5 Citations |
| 1 | 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. (Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG, Siegel CL, Fischer KC, Kibel AS, Andriole GL, Miller TR) J Nucl Med 2013 May;54(5):699-706 72 Citations |
| 1 | Evaluation of Adherence to Quality Measures for Prostate Cancer Radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) Survey. (Zelefsky MJ, Lee WR, Zietman A, Khalid N, Crozier C, Owen J, Wilson JF) Pract Radiat Oncol 2013 Jan;3(1):2-8 22 Citations |
| 2 | Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. (Cury FL, Hunt D, Roach M 3rd, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C) Cancer 2013 Jun 01;119(11):1999-2004 17 Citations |
| 1 | High-resolution transrectal ultrasound: pilot study of a novel technique for imaging clinically localized prostate cancer. (Pavlovich CP, Cornish TC, Mullins JK, Fradin J, Mettee LZ, Connor JT, Reese AC, Askin FB, Luck R, Epstein JI, Burke HB) Urol Oncol 2014 Jan;32(1):34.e27-32 52 Citations |
| 1 | Early postoperative urinary and sexual function predicts functional recovery 1 year after prostatectomy. (Ellison JS, He C, Wood DP) J Urol 2013 Oct;190(4):1233-8 5 Citations |
| 1 | AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. (Hong SK, Jeong JH, Chan AM, Park JI) Exp Cell Res 2013 Jul 15;319(12):1732-1743 22 Citations |
| 1 | Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. (Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A, Fachal L, Gómez-Caamaño A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein BS, Ostrer H) Radiother Oncol 2013 Jun;107(3):372-6 76 Citations |
| 6 | Duloxetine for the treatment of post-prostatectomy stress urinary incontinence. (Neff D, Guise A, Guralnick ML, Langenstroer P, See WA, Jacobsohn KM, O'Connor RC) Can Urol Assoc J 2013;7(5-6):E260-2 17 Citations |
| 1 | The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate. (Hall WA, Nickleach DC, Master VA, Prabhu RS, Rossi PJ, Godette K, Cooper S, Jani AB) Cancer 2013 Sep 15;119(18):3272-9 35 Citations |
| 2 | RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. (Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA) Prostate Cancer Prostatic Dis 2013 Dec;16(4):382-6 33 Citations |
| 1 | Pro-survival and pro-growth effects of stress-induced nitric oxide in a prostate cancer photodynamic therapy model. (Bhowmick R, Girotti AW) Cancer Lett 2014 Feb 01;343(1):115-22 64 Citations |
| 1 | An assessment of PTV margin based on actual accumulated dose for prostate cancer radiotherapy. (Wen N, Kumarasiri A, Nurushev T, Burmeister J, Xing L, Liu D, Glide-Hurst C, Kim J, Zhong H, Movsas B, Chetty IJ) Phys Med Biol 2013 Nov 07;58(21):7733-44 17 Citations |
| 1 | A novel approach for establishing benchmark CBCT/CT deformable image registrations in prostate cancer radiotherapy. (Kim J, Kumar S, Liu C, Zhong H, Pradhan D, Shah M, Cattaneo R, Yechieli R, Robbins JR, Elshaikh MA, Chetty IJ) Phys Med Biol 2013 Nov 21;58(22):8077-97 35 Citations |
| 1 | Evaluation of interfraction patient setup errors for image-guided prostate and head-and-neck radiotherapy using kilovoltage cone beam and megavoltage fan beam computed tomography (Qi XS, Wu S, Newman F, Li XA, Hu AY) Journal of Radiotherapy in Practice December 2013;12(4):334-343 5 Citations |
| 1 | Re: use of advanced treatment technologies among men at low risk of dying from prostate cancer. (See WA) Eur Urol 2014 Jan;65(1):250 |
| 1 | Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. (Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, Grenade C, Ke J, Zhang C, Chen H, Nephew KP, Huang TH, Liu Z, Jin VX, Wang Q) Nucleic Acids Res 2014 Apr;42(6):3607-22 122 Citations |
| 1 | Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study. (Venkatasubramanian PN, Brendler CB, Plunkett BA, Crawford SE, Fitchev PS, Morgan G, Cornwell ML, McGuire MS, Wyrwicz AM, Doll JA) Prostate 2014 Feb;74(3):326-35 38 Citations |
| 3 | Assessment and management of interfractional variations in daily diagnostic-quality-CT guided prostate-bed irradiation after prostatectomy. (Liu F, Ahunbay E, Lawton C, Li XA) Med Phys 2014 Mar;41(3):031710 29 Citations |
| 1 | Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate. (Hall WA, Colbert L, Nickleach D, Shelton J, Marcus DM, Switchenko J, Rossi PJ, Godette K, Cooper S, Jani AB) Pract Radiat Oncol 2013;3(4):e157-64 16 Citations |
| 1 | Preliminary evaluation of the dosimetric accuracy of the in vivo plastic scintillation detector OARtrac system for prostate cancer treatments. (Klawikowski SJ, Zeringue C, Wootton LS, Ibbott GS, Beddar S) Phys Med Biol 2014 May 07;59(9):N27-36 13 Citations |
| 2 | Comparison of clinical outcomes between "ideal" and "nonideal" transobturator male sling patients for treatment of postprostatectomy incontinence. (Sturm RM, Guralnick ML, Stone AR, Bales GT, Dangle PP, O'Connor RC) Urology 2014 May;83(5):1186-8 36 Citations |
| 1 | Fluorodeoxyglucose positron emission tomography/computed tomography imaging of a patient with squamous cell carcinoma of prostate. (Kara Gedik G, Yavas G, Akand M, Celik E, Sari O) Case Rep Med 2014;2014:860570 6 Citations |
| 1 | Predictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction. (Zhao YR, Liu WZ, Guralnick M, Niu WJ, Wang Y, Sun G, Xu Y) Int J Urol 2014 Oct;21(10):1035-40 45 Citations |
| 1 | SU-E-J-239: IMRT Planning of Prostate Cancer for a MRI-Linac Based On MRI Only. (Chen X, Prior P, Paulson E, Lawton C, Li X) Med Phys 2014 Jun;41(6):212 |
| 1 | Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79,000 women. (Barrdahl M, Canzian F, Joshi AD, Travis RC, Chang-Claude J, Auer PL, Gapstur SM, Gaudet M, Diver WR, Henderson BE, Haiman CA, Schumacher FR, Le Marchand L, Berg CD, Chanock SJ, Hoover RN, Rudolph A, Ziegler RG, Giles GG, Baglietto L, Severi G, Hankinson SE, Lindström S, Willet W, Hunter DJ, Buring JE, Lee IM, Zhang S, Dossus L, Cox DG, Khaw KT, Lund E, Naccarati A, Peeters PH, Quirós JR, Riboli E, Sund M, Trichopoulos D, Prentice RL, Kraft P, Kaaks R, Campa D) Hum Mol Genet 2014 Oct 01;23(19):5260-70 36 Citations |
| 1 | Post-translational regulation of COX2 activity by FYN in prostate cancer cells. (Alexanian A, Miller B, Chesnik M, Mirza S, Sorokin A) Oncotarget 2014 Jun 30;5(12):4232-43 25 Citations |
| 1 | Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). (Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr) Cancer Epidemiol Biomarkers Prev 2014 Aug;23(8):1638-48 6 Citations |
| 1 | Point/Counterpoint. Online adaptive planning for prostate cancer radiotherapy is necessary and ready now. (Li XA, Wu Q, Orton CG) Med Phys 2014 Aug;41(8):080601 9 Citations |
| 2 | Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. (Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L) Eur Urol 2015 Jan;67(1):33-41 610 Citations |
| 1 | Prostate cancer risk locus at 8q24 as a regulatory hub by physical interactions with multiple genomic loci across the genome. (Du M, Yuan T, Schilter KF, Dittmar RL, Mackinnon A, Huang X, Tschannen M, Worthey E, Jacob H, Xia S, Gao J, Tillmans L, Lu Y, Liu P, Thibodeau SN, Wang L) Hum Mol Genet 2015 Jan 01;24(1):154-66 48 Citations |
| 1 | How we treat early systemic prostate cancer in older men. (Kilari D, Dale W, Mohile SG) J Geriatr Oncol 2014 Oct 01;5(4):337-42 9 Citations |
| 1 | Transperineal template-guided mapping biopsy of the prostate. (Sivaraman A, Sanchez-Salas R, Barret E, Ahallal Y, Rozet F, Galiano M, Prapotnich D, Cathelineau X) Int J Urol 2015 Feb;22(2):146-51 40 Citations |
| 1 | Prostate histoscanning true targeting guided prostate biopsy: initial clinical experience. (Sivaraman A, Sanchez-Salas R, Barret E, Macek P, Validire P, Galiano M, Rozet F, Cathelineau X) World J Urol 2015 Oct;33(10):1475-9 14 Citations |
| 1 | MRS measured fatty acid composition of periprostatic adipose tissue correlates with pathological measures of prostate cancer aggressiveness. (Iordanescu G, Brendler C, Crawford SE, Wyrwicz AM, Venkatasubramanian PN, Doll JA) J Magn Reson Imaging 2015 Sep;42(3):651-7 18 Citations |
| 1 | Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. (Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C, Chen J, Zynger DL, Yan PS, Huang J, Nephew KP, Huang TH, Lin S, Clinton SK, Li W, Jin VX, Wang Q) EMBO J 2015 Feb 12;34(4):502-16 76 Citations |
| 1 | Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. (Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM) J Clin Oncol 2015 Feb 01;33(4):332-9 122 Citations |
| 1 | Prostate Cancer (Michalski JM, Pisansky TM, Lawton CAF, Potters L) Clinical Radiation Oncology 1 January 2015:1038-1095.e18 3 Citations |
| 3 | Thermoacoustic contrast of prostate cancer due to heating by very high frequency irradiation. (Patch SK, Hull D, Thomas M, Griep SK, Jacobsohn K, See WA) Phys Med Biol 2015 Jan 21;60(2):689-708 18 Citations |
| 1 | Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database. (Shukla ME, Yu C, Reddy CA, Stephans KL, Klein EA, Abdel-Wahab M, Ciezki J, Tendulkar RD) Clin Genitourin Cancer 2015 Feb;13(1):17-21 18 Citations |
| 1 | Androgen receptors beyond prostate cancer: an old marker as a new target. (Munoz J, Wheler JJ, Kurzrock R) Oncotarget 2015 Jan 20;6(2):592-603 39 Citations |
| 1 | Prostate cancer and vasectomy: déjà vu! (Sokal DC, Labrecque M, Belker AM, Faraday MM, Honig S, Marmar JL, Ross LS, Sandlow JI, Sharlip ID) J Clin Oncol 2015 Feb 20;33(6):669-70 4 Citations |
| 1 | An adaptive MR-CT registration method for MRI-guided prostate cancer radiotherapy. (Zhong H, Wen N, Gordon JJ, Elshaikh MA, Movsas B, Chetty IJ) Phys Med Biol 2015 Apr 07;60(7):2837-51 32 Citations |
| 2 | Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. (Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L) Oncotarget 2015 Jun 30;6(18):16411-21 43 Citations |
| 1 | Clinical utility of transperineal template-guided mapping biopsy of the prostate after negative magnetic resonance imaging-guided transrectal biopsy. (Sivaraman A, Sanchez-Salas R, Ahmed HU, Barret E, Cathala N, Mombet A, Uriburu Pizarro F, Carneiro A, Doizi S, Galiano M, Rozet F, Prapotnich D, Cathelineau X) Urol Oncol 2015 Jul;33(7):329.e7-11 10 Citations |
| 1 | Oligometastatic prostate cancer to the navicular bone: case report. (Reyes DK, Miller JA, Cerrato RA, Pienta KJ) Urol Case Rep 2015 May 01;3(3):59-62 4 Citations |
| 1 | ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. (Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY) J Nucl Med 2015 Jul;56(7):1003-1010 180 Citations |
| 1 | Accelerated migration and invasion of prostate cancer cells after a photodynamic therapy-like challenge: Role of nitric oxide. (Fahey JM, Girotti AW) Nitric Oxide 2015 Sep 15;49:47-55 76 Citations |
| 1 | Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. (Krauss DJ, Hu C, Bahary JP, Souhami L, Gore EM, Chafe SM, Leibenhaut MH, Narayan S, Torres-Roca J, Michalski J, Zeitzer KL, Donavanik V, Sandler H, McGowan DG, Jones CU, Shipley WU) Int J Radiat Oncol Biol Phys 2015 Jul 15;92(4):863-73 29 Citations |
| 1 | A Qualitative Study Exploring the Perceptions of Sedentary Behavior in Prostate Cancer Survivors Receiving Androgen-Deprivation Therapy. (Trinh L, Arbour-Nicitopoulos KP, Sabiston CM, Alibhai SM, Jones JM, Berry SR, Loblaw A, Faulkner GE) Oncol Nurs Forum 2015 Jul;42(4):398-406 20 Citations |
| 1 | Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. (Feijoo ER, Sivaraman A, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Prapotnich D, Cathala N, Mombet A, Cathelineau X) Eur Urol 2016 Feb;69(2):214-20 139 Citations |
| 1 | Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer. (Haffty BG, Lawton CA, Sandler H) JAMA Oncol 2015 Aug;1(5):688-9 1 Citation |
| 1 | Molecular landscape of prostate cancer: implications for current clinical trials. (Khemlina G, Ikeda S, Kurzrock R) Cancer Treat Rev 2015 Nov;41(9):761-6 63 Citations |
| 1 | The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate. (Hall WA, Nickleach DC, Master VA, Prabhu RS, Rossi PJ, Godette K, Cooper S, Jani AB ) Cancer. 2013 Sep 15;119(18):3272-9 |
| 1 | Re: can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. (Sivaraman A, Sanchez-Salas R) Eur Urol 2015 Oct;68(4):738 21 Citations |
| 1 | DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. (Horning AM, Awe JA, Wang CM, Liu J, Lai Z, Wang VY, Jadhav RR, Louie AD, Lin CL, Kroczak T, Chen Y, Jin VX, Abboud-Werner SL, Leach RJ, Hernandez J, Thompson IM, Saranchuk J, Drachenberg D, Chen CL, Mai S, Huang TH) Prostate 2015 Nov;75(15):1790-801 24 Citations |
| 1 | Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. (Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA) Eur Urol 2016 Feb;69(2):204-10 42 Citations |
| 1 | Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. (Tay KJ, Polascik TJ, Elshafei A, Cher ML, Given RW, Mouraviev V, Ross AE, Jones JS) J Endourol 2016 Jan;30(1):43-8 30 Citations |
| 1 | Superficial Implantation of the I-Stop TOMS Transobturator Sling in the Treatment of Postprostatectomy Urinary Incontinence: Description of a Novel Technique and 1-Year Outcomes. (Galiano M, Guillot-Tantay C, Sivaraman A, Slaoui H, Barret E, Rozet F, Sanchez-Salas R, Cathelineau X) Urology 2016 Apr;90:195-8 13 Citations |
| 2 | Toward Quantitative Whole Organ Thermoacoustics With a Clinical Array Plus One Very Low-Frequency Channel Applied to Prostate Cancer Imaging. (Patch SK, Hull D, See WA, Hanson GW) IEEE Trans Ultrason Ferroelectr Freq Control 2016 Feb;63(2):245-55 47 Citations |
| 1 | Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. (Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin CL, Goodfellow PJ, Clinton SK, Jin VX, Chen CL, Huang TH, Wang Q) Nucleic Acids Res 2016 May 19;44(9):4105-22 34 Citations |
| 1 | Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer. (Brower JV, Forman JD, Kupelian PA, Petereit DG, Gondi V, Lawton CA, Anger N, Saha S, Chappell R, Ritter MA) Radiother Oncol 2016 Jan;118(1):99-104 11 Citations |
| 1 | Focal Therapy for Prostate Cancer: An "À la Carte" Approach. (Sivaraman A, Barret E) Eur Urol 2016 Jun;69(6):973-5 101 Citations |
| 1 | Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. (Gaudet MM, Barrdahl M, Lindström S, Travis RC, Auer PL, Buring JE, Chanock SJ, Eliassen AH, Gapstur SM, Giles GG, Gunter M, Haiman C, Hunter DJ, Joshi AD, Kaaks R, Khaw KT, Lee IM, Le Marchand L, Milne RL, Peeters PH, Sund M, Tamimi R, Trichopoulou A, Weiderpass E, Yang XR, Prentice RL, Feigelson HS, Canzian F, Kraft P) Breast Cancer Res Treat 2016 Feb;155(3):531-40 1 Citation |
| 1 | Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques. (Au BC, Lee CJ, Lopez-Perez O, Foltz W, Felizardo TC, Wang JCM, Huang J, Fan X, Madden M, Goldstein A, Jaffray DA, Moloo B, McCart JA, Medin JA) Biomedicines 2016 Feb 19;4(1) 1 Citation |
| 1 | Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. (Sivaraman A, Ordaz Jurado G, Cathelineau X, Barret E, Dell'Oglio P, Joniau S, Bianchi M, Briganti A, Spahn M, Bastian P, Chun J, Chlosta P, Gontero P, Graefen M, Jeffrey Karnes R, Marchioro G, Tombal B, Tosco L, van der Poel HH, Sanchez-Salas R) World J Urol 2016 Oct;34(10):1367-72 15 Citations |
| 1 | Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis. (Wang Y, Jadhav RR, Liu J, Wilson D, Chen Y, Thompson IM, Troyer DA, Hernandez J, Shi H, Leach RJ, Huang TH, Jin VX) Sci Rep 2016 Feb 29;6:22051 18 Citations |
| 1 | Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. (Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS) Nat Med 2016 Apr;22(4):369-78 625 Citations |
| 1 | Robot-assisted Versus Standard Laparoscopy for Simple Prostatectomy: Multicenter Comparative Outcomes. (Pavan N, Zargar H, Sanchez-Salas R, Castillo O, Celia A, Gallo G, Sivaraman A, Cathelineau X, Autorino R) Urology 2016 May;91:104-10 44 Citations |
| 1 | Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. (Ahmed M, Dorling L, Kerns S, Fachal L, Elliott R, Partliament M, Rosenstein BS, Vega A, Gómez-Caamaño A, Barnett G, Dearnaley DP, Hall E, Sydes M, Burnet N, Pharoah PD, Eeles R, West CM) Br J Cancer 2016 May 10;114(10):1165-74 20 Citations |
| 6 | MRI-based IMRT planning for MR-linac: comparison between CT- and MRI-based plans for pancreatic and prostate cancers. (Prior P, Chen X, Botros M, Paulson ES, Lawton C, Erickson B, Li XA) Phys Med Biol 2016 May 21;61(10):3819-42 40 Citations |
| 1 | Minimally Invasive Salvage Prostatectomy After Primary Radiation or Ablation Treatment. (Linares Espinós E, Sánchez-Salas R, Sivaraman A, Perez-Reggeti JI, Barret E, Rozet F, Galiano M, Prapotnich D, Cathelineau X) Urology 2016 Aug;94:111-6 32 Citations |
| 2 | MRI-guided prostate adaptive radiotherapy - A systematic review. (McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, Mahmood U, Pos F, van As N, van Herk M, Vesprini D, van der Voort van Zyp J, Tree A, Choudhury A, MR-Linac consortium) Radiother Oncol 2016 Jun;119(3):371-80 145 Citations |
| 2 | The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge. (Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, Gupta SN, Besa C, Kalpathy-Cramer J, Mountz JM, Laymon CM, Muzi M, Schmainda K, Cao Y, Chenevert TL, Taouli B, Yankeelov TE, Fennessy F, Li X) Tomography 2016 Mar;2(1):56-66 |
| 1 | Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. (Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N) Nature 2016 May 26;533(7604):547-51 157 Citations |
| 1 | Evolution of prostate biopsy techniques. Looking back on a meaningful journey. (Sivaraman A, Sanchez-Salas R, Castro-Marin M, Barret E, Guillot-Tantay C, Prapotnich D, Cathelineau X) Actas Urol Esp 2016 Oct;40(8):492-8 9 Citations |
| 1 | Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. (Mak RH, Hunt D, Efstathiou JA, Heney NM, Jones CU, Lukka HR, Bahary JP, Patel M, Balogh A, Nabid A, Leibenhaut MH, Hamstra DA, Roof KS, Jeffrey Lee R, Gore EM, Sandler HM, Shipley WU) Urol Oncol 2016 Oct;34(10):430.e1-7 19 Citations |
| 1 | Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells. (Rosati R, Chen B, Patki M, McFall T, Ou S, Heath E, Ratnam M, Qin Z) Mol Pharmacol 2016 Sep;90(3):225-37 21 Citations |
| 1 | High intensity focused ultrasound for Focal Therapy of prostate cancer. (Sivaraman A) Arch Esp Urol 2016 Jul;69(6):311-6 6 Citations |
| 1 | [Localized prostate cancer Focal Therapy: "A la carte" Model]. (Linares Espinós E, Barret E, Sivaraman A, Pérez-Reggeti JI, Sánchez-Salas R, Rozet F, Galiano M, Cathelineau X) Arch Esp Urol 2016 Jul;69(6):345-52 8 Citations |
| 1 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. (Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS) N Engl J Med 2016 Aug 04;375(5):443-53 1498 Citations |
| 1 | Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. (Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CML, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J, International Radiogenomics Consortium (RgC)) Radiother Oncol 2016 Dec;121(3):431-439 113 Citations |
| 1 | Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. (Kerns SL, Dorling L, Fachal L, Bentzen S, Pharoah PD, Barnes DR, Gómez-Caamaño A, Carballo AM, Dearnaley DP, Peleteiro P, Gulliford SL, Hall E, Michailidou K, Carracedo Á, Sia M, Stock R, Stone NN, Sydes MR, Tyrer JP, Ahmed S, Parliament M, Ostrer H, Rosenstein BS, Vega A, Burnet NG, Dunning AM, Barnett GC, West CM, Radiogenomics Consortium) EBioMedicine 2016 Aug;10:150-63 80 Citations |
| 1 | Clinical performance of transperineal template guided mapping biopsy for therapeutic decision making in low risk prostate cancer. (Ahallal Y, Sanchez-Salas R, Sivaraman A, Barret E, Secin FP, Validire P, Rozet F, Galiano M, Cathelineau X) Actas Urol Esp 2016 Dec;40(10):615-620 3 Citations |
| 1 | High intensity focused ultrasound with Focal-One® device: Prostate-specific antigen impact and morbidity evaluation during the initial experience. (Perez-Reggeti JI, Sanchez-Salas R, Sivaraman A, Linares Espinos E, de Gracia-Nieto AE, Barret E, Galiano M, Rozet F, Fregeville A, Renard-Penna R, Cathala N, Mombet A, Prapotnich D, Cathelineau X) Actas Urol Esp 2016 Dec;40(10):608-614 15 Citations |
| 1 | Recovery of urinary continence after radical prostatectomy. (Capogrosso P, Sanchez-Salas R, Salonia A, Cathala N, Mombet A, Sivaraman A, Barret E, Montorsi F, Cathelineau X) Expert Rev Anticancer Ther 2016 Oct;16(10):1039-52 9 Citations |
| 1 | Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer. (Flynn T, Guancial EA, Kilari M, Kilari D) Clin Genitourin Cancer 2017 Feb;15(1):e95-e97 11 Citations |
| 1 | A Hybrid Adaptive Replanning Approach for Prostate Stereotactic Body Radiation Therapy (O. Ates
E.E. Ahunbay
C.A.F. Lawton
A. Li) International Journal of Radiation Oncology, Biology, Physics POSTER VIEWING ABSTRACT| VOLUME 96, ISSUE 2, SUPPLEMENT , E668-E669, OCTOBER 01, 2016 |
| 1 | NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer: Prostate-Specific Quality of Life Results (D. Watkins Bruner
S.L. Pugh
W.R. Lee
J.J. Dignam
D. Low
G.P. Swanson
A.B. Shah
D.P. D'Souza
J.M. Michalski
I.S. Dayes
S.A. Seaward
P.L. Nguyen
W.A. Hall
T.M. Pisansky
Y. Chen
H.M. Sandler
B. Movsas
) International Journal of Radiation Oncology, Biology, Physics ORAL SCIENTIFIC SESSION| VOLUME 96, ISSUE 2, SUPPLEMENT , S2-S3, OCTOBER 01, 2016 |
| 1 | Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. (Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT) Oncotarget 2017 Jan 10;8(2):3724-3745 114 Citations |
| 1 | Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles. (Rana S, Cheng C, Zhao L, Park S, Larson G, Vargas C, Dunn M, Zheng Y) J Med Radiat Sci 2017 Mar;64(1):18-24 14 Citations |
| 1 | The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth. (Rosati R, Patki M, Chari V, Dakshnamurthy S, McFall T, Saxton J, Kidder BL, Shaw PE, Ratnam M) J Biol Chem 2016 Dec 09;291(50):25983-25998 15 Citations |
| 1 | Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence. (Hempel HA, Cuka NS, Kulac I, Barber JR, Cornish TC, Platz EA, De Marzo AM, Sfanos KS) Prostate 2017 Mar;77(4):412-424 59 Citations |
| 1 | Higher number of transrectal ultrasound guided prostate biopsy cores is associated with higher blood loss and perioperative complications in robot assisted radical prostatectomy. (Carneiro A, Sivaraman A, Sanchez-Salas R, Nunes-Silva I, Baghdadi M, Srougi V, di Trapani E, Uriburu Pizzaro F, Doizi S, Barret E, Rozet F, Galiano M, Cathelineau X) Actas Urol Esp 2017 Apr;41(3):155-161 10 Citations |
| 1 | The Effect of Obesity on Perioperative Outcomes for Open and Minimally Invasive Prostatectomy. (Johnson SC, Packiam VT, Golan S, Cohen AJ, Nottingham CU, Smith ND) Urology 2017 Feb;100:111-116 18 Citations |
| 2 | Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. (Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY) Semin Radiat Oncol 2017 Jan;27(1):11-20 12 Citations |
| 1 | Learning curve of minimally invasive radical prostatectomy: Comprehensive evaluation and cumulative summation analysis of oncological outcomes. (Sivaraman A, Sanchez-Salas R, Prapotnich D, Yu K, Olivier F, Secin FP, Barret E, Galiano M, Rozet F, Cathelineau X) Urol Oncol 2017 Apr;35(4):149.e1-149.e6 44 Citations |
| 1 | Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. (Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM) Int J Radiat Oncol Biol Phys 2017 Mar 01;97(3):511-515 7 Citations |
| 1 | Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. (Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG) N Engl J Med 2017 Feb 02;376(5):417-428 594 Citations |
| 1 | Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214-20. (Sivaraman A, Barret E) Eur Urol 2017 May;71(5):e148-e149 |
| 1 | Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. (Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM) Cancer 2017 Jul 01;123(13):2489-2496 17 Citations |
| 1 | Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. (Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH, Robertson CN, Sanchez-Salas R, Scionti S, Sivaraman A, de la Rosette J, Polascik TJ) Prostate Cancer Prostatic Dis 2017 Sep;20(3):294-299 142 Citations |
| 1 | Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. (Gandaglia G, Karnes RJ, Sivaraman A, Moschini M, Fossati N, Zaffuto E, DellʼOglio P, Cathelineau X, Montorsi F, Sanchez-Salas R, Briganti A) Urol Oncol 2017 Jul;35(7):461.e7-461.e14 23 Citations |
| 1 | Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. (Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin CL, Goodfellow PJ, Clinton SK, Jin VX, Chen CL, Huang TH, Wang Q) Nucleic Acids Res 2017 Jun 20;45(11):6993 7 Citations |
| 1 | Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. (Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM) Int J Radiat Oncol Biol Phys 2017 Jun 01;98(2):296-303 127 Citations |
| 2 | PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform. (Ronen S, Abbott DW, Kravtsov O, Abdelkader A, Xu Y, Banerjee A, Iczkowski KA) Hum Pathol 2017 Jul;65:85-91 36 Citations |
| 1 | The relationship between anxiety about prostate cancer among patients with biochemical cancer recurrence and the use of complementary and alternative medicines, diet, and exercise (Lee RT, Hemmerich JA, Kwon N, Bylow K, Stadler WM, Mohile SG, Dale W) Family Medicine and Community Health 1 July 2017;5(2):139-148 2 Citations |
| 1 | The effects of the order of multiple imputation in subset analysis examining the association between body mass index (BMI) and transrectal ultrasound prostate weight. (IB Helenowski, H Demirtas, JA Doll, BD Jovanovic, MJ Gurley, LP Trapp, TM Kuzel. ) Converg. Sci. Phys. Oncol. 2: 035003, 2016 |
| 1 | Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low and Intermediate Risk Prostate Cancer: Oncologic and Functional Outcomes. (Garcia-Barreras S, Sanchez-Salas R, Sivaraman A, Barret E, Secin F, Nunes-Silva I, Linares-Espinós E, Rozet F, Galiano M, Cathelineau X) J Urol 2018 Jan;199(1):140-146 38 Citations |
| 6 | Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. (Hurrell SL, McGarry SD, Kaczmarowski A, Iczkowski KA, Jacobsohn K, Hohenwalter MD, Hall WA, See WA, Banerjee A, Charles DK, Nevalainen MT, Mackinnon AC, LaViolette PS) J Med Imaging (Bellingham) 2018 Jan;5(1):011004 40 Citations |
| 1 | Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408. (Nichols RC, Hu C, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Gore EM, Balogh AG, McGowan D, Michalski J, Raben A, Rudoler S, Jones CU, Sandler H) Adv Radiat Oncol 2017;2(4):608-614 16 Citations |
| 1 | Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response. (Horning AM, Wang Y, Lin CK, Louie AD, Jadhav RR, Hung CN, Wang CM, Lin CL, Kirma NB, Liss MA, Kumar AP, Sun L, Liu Z, Chao WT, Wang Q, Jin VX, Chen CL, Huang TH) Cancer Res 2018 Feb 15;78(4):853-864 101 Citations |
| 1 | Inguinal Hernia Repair Around Prostatectomy (Masnyj S, Goldblatt MI) Surgical Principles in Inguinal Hernia Repair A Comprehensive Guide to Anatomy and Operative Techniques 1 January 2018:153-158 |
| 2 | Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment? (Pathmanathan AU, van As NJ, Kerkmeijer LGW, Christodouleas J, Lawton CAF, Vesprini D, van der Heide UA, Frank SJ, Nill S, Oelfke U, van Herk M, Li XA, Mittauer K, Ritter M, Choudhury A, Tree AC) Int J Radiat Oncol Biol Phys 2018 Feb 01;100(2):361-373 160 Citations |
| 1 | Diagnosis of Prostate Cancer with Noninvasive Estimation of Prostate Tissue Composition by Using Hybrid Multidimensional MR Imaging: A Feasibility Study. (Chatterjee A, Bourne RM, Wang S, Devaraj A, Gallan AJ, Antic T, Karczmar GS, Oto A) Radiology 2018 Jun;287(3):864-873 102 Citations |
| 1 | Role of Prostate MR Imaging in Radiation Oncology. (Ménard C, Paulson E, Nyholm T, McLaughlin P, Liney G, Dirix P, van der Heide UA) Radiol Clin North Am 2018 Mar;56(2):319-325 16 Citations |
| 2 | STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. (Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT) Clin Cancer Res 2018 Apr 15;24(8):1917-1931 51 Citations |
| 1 | Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. (Lee S, Kerns S, Ostrer H, Rosenstein B, Deasy JO, Oh JH) Int J Radiat Oncol Biol Phys 2018 May 01;101(1):128-135 85 Citations |
| 1 | Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer? (Sivaraman A, Benfante N, Touijer K, Coleman J, Scardino P, Laudone V, Eastham J) Investig Clin Urol 2018 Mar;59(2):83-90 10 Citations |
| 1 | Physical activity and annual medical outlay in U.S. colorectal, breast and prostate cancer survivors. (Yan AF, Wang Y, Ng AV) Prev Med Rep 2018 Mar;9:118-123 14 Citations |
| 1 | Prostate Cancer: Improving the Flow of Research. (Lawton CAF) Radiology 2018 Apr;287(1):5-9 3 Citations |
| 1 | Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients. (Sanchez-Salas R, de la Rosette J, Polascik TJ, Carneiro A, Sivaraman A, Cathelineau X, Walz J) Eur Urol 2018 Nov;74(5):537-539 6 Citations |
| 1 | Outcomes of salvage radical prostatectomy following more than one failed local therapy. (Sivaraman A, Scardino P, Eastham J) Investig Clin Urol 2018 May;59(3):152-157 4 Citations |
| 1 | Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. (Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, Cheng X, Antonarakis ES, Wang QE, Liu Z, Huang TH, Jin VX, Clinton SK, Luo J, Huang J, Wang Q) Proc Natl Acad Sci U S A 2018 Jun 26;115(26):6810-6815 135 Citations |
| 1 | Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. (Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L) Prostate Cancer Prostatic Dis 2018 Sep;21(3):411-418 37 Citations |
| 1 | Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. (Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z) Nat Commun 2018 Jun 11;9(1):2256 90 Citations |
| 1 | Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. (Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA, Profile Study, Australian Prostate Cancer BioResource (APCB), IMPACT Study, Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Cancer of the Prostate in Sweden (CAPS), Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium) Nat Genet 2018 Jul;50(7):928-936 698 Citations |
| 1 | Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. (Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A, PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM) Cell 2018 Jun 14;173(7):1770-1782.e14 506 Citations |
| 1 | The Medical College of Wisconsin 39 (MCW39): A Magnetic Resonance Image Template of the Prostate to Facilitate Group Analysis (McGarry, Sean Budde, Matthew Hurrell, Sarah Ickzowski, Kenneth Griffin, Michael Duvnjak, Petar Jacobsohn, Kenneth Hall, William Hohenwalter, Mark Nencka, Andrew LaViolette, Peter) Proc. ISMRM (2018): 4499 |
| 1 | Predictive Cytological Topography (PiCT): a Radio-Pathomics Approach to Mapping Prostate Cancer (McGarry, Sean Hurrell, Sarah Iczkowski, Kenneth Kaczmarowski, Amy Banerjee, Anjishnu Keuter, Tucker Jacobsohn, Kenneth Hall, William Nevalainen, Marja Hohenwalter, Mark See, William Nencka, Andrew LaViolette, Peter) Proc. ISMRM (2018): 0775 |
| 1 | The RadPath Surfer: A Radiologic-Pathologic tool for visualizing prostate cancer histology (McGarry, Sean Hurrell, Sarah Jacobsohn, Kenneth Iczkowski, Kenneth Griffin, Michael Duvnjak, Petar Nencka, Andrew Hohenwalter, Mark LaViolette, Peter) Proc. ISMRM (2018): 4387 |
| 5 | Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer. (McGarry SD, Hurrell SL, Iczkowski KA, Hall W, Kaczmarowski AL, Banerjee A, Keuter T, Jacobsohn K, Bukowy JD, Nevalainen MT, Hohenwalter MD, See WA, LaViolette PS) Int J Radiat Oncol Biol Phys 2018 Aug 01;101(5):1179-1187 53 Citations |
| 1 | Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. (Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA) Int J Radiat Oncol Biol Phys 2018 Oct 01;102(2):287-295 69 Citations |
| 1 | Roles of microRNA in prostate cancer cell metabolism. (Kasomva K, Sen A, Paulraj MG, Sailo S, Raphael V, Puro KU, Assumi SR, Ignacimuthu S) Int J Biochem Cell Biol 2018 Sep;102:109-116 14 Citations |
| 1 | Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. (Rosati R, Polin L, Ducker C, Li J, Bao X, Selvakumar D, Kim S, Xhabija B, Larsen M, McFall T, Huang Y, Kidder BL, Fribley A, Saxton J, Kakuta H, Shaw P, Ratnam M) Clin Cancer Res 2018 Dec 15;24(24):6509-6522 16 Citations |
| 1 | Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities. (Xiao C, Moughan J, Movsas B, Konski AA, Hanks GE, Cox JD, Roach M 3rd, Zeitzer KL, Lawton CA, Peters CA, Rosenthal SA, Hsu IJ, Horwitz EM, Mishra MV, Michalski JM, Parliament MB, D'Souza DP, Pugh SL, Bruner DW) Adv Radiat Oncol 2018;3(3):405-411 3 Citations |
| 1 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. (Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H) J Clin Oncol 2018 Oct 11;36(34):JCO1801097 155 Citations |
| 2 | Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. (Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM) Lancet Oncol 2018 Nov;19(11):1504-1515 223 Citations |
| 1 | Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. (Kayano PP, Carneiro A, Castilho TML, Sivaraman A, Claros OR, Baroni RH, Garcia RG, Mariotti GC, Smaletz O, Filippi RZ, Lemos GC) Int Braz J Urol 2018;44(6):1106-1113 24 Citations |
| 1 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. (Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H) Pract Radiat Oncol 2018;8(6):354-360 210 Citations |
| 1 | Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. (Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R) Cancer Biol Ther 2019;20(2):219-226 47 Citations |
| 1 | Germline variation at 8q24 and prostate cancer risk in men of European ancestry. (Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C, Mucci L, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L, Grindedal EM, Strom SS, Neal DE, Hamdy FC, Donovan JL, Travis RC, Hamilton RJ, Rosenstein B, Lu YJ, Giles GG, Kibel AS, Vega A, Bensen JT, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Gago-Dominguez M, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Schaid DJ, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Wiklund F, Chanock SJ, Easton DF, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA) Nat Commun 2018 Nov 05;9(1):4616 50 Citations |
| 1 | Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate. (Chatterjee A, Tokdemir S, Gallan AJ, Yousuf A, Antic T, Karczmar GS, Oto A) AJR Am J Roentgenol 2019 Jan;212(1):124-129 18 Citations |
| 1 | Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized Prostate Cancer. (Reeve BB, Wang M, Weinfurt K, Flynn KE, Usinger DS, Chen RC) J Sex Med 2018 Dec;15(12):1792-1810 12 Citations |
| 1 | CDK12-mutated prostate cancer: Clinical outcomes with standard therapies and immune checkpoint blockade (Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A) JCO Precision Oncology 2019;3:382-392 83 Citations |
| 1 | Identification of targets for prostate cancer immunotherapy. (Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C) Prostate 2019 Apr;79(5):498-505 26 Citations |
| 1 | Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552-5: Comparing Apples to Oranges: A Self-fulfilling Prophecy? (Kishan AU, Hall WA, Spratt DE) Eur Urol 2019 May;75(5):e133-e134 |
| 1 | Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review. (Marra G, Gontero P, Walz JC, Sivaraman A, Tourinho-Barbosa R, Cathelineau X, Sanchez-Salas R) World J Urol 2019 Aug;37(8):1517-1534 27 Citations |
| 1 | Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. (Bruner DW, Pugh SL, Lee WR, Hall WA, Dignam JJ, Low D, Swanson GP, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Nguyen PL, Pisansky TM, Chen Y, Sandler HM, Movsas B) JAMA Oncol 2019 May 01;5(5):664-670 51 Citations |
| 1 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. (Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H) J Urol 2019 Mar;201(3):528-534 81 Citations |
| 2 | The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge, Part II. (Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, Gupta SN, Besa C, Kalpathy-Cramer J, Mountz JM, Laymon CM, Muzi M, Kinahan PE, Schmainda K, Cao Y, Chenevert TL, Taouli B, Yankeelov TE, Fennessy F, Li X) Tomography 2019 Mar;5(1):99-109 21 Citations |
| 5 | Gleason Probability Maps: A Radiomics Tool for Mapping Prostate Cancer Likelihood in MRI Space. (McGarry SD, Bukowy JD, Iczkowski KA, Unteriner JG, Duvnjak P, Lowman AK, Jacobsohn K, Hohenwalter M, Griffin MO, Barrington AW, Foss HE, Keuter T, Hurrell SL, See WA, Nevalainen MT, Banerjee A, LaViolette PS) Tomography 2019 Mar;5(1):127-134 48 Citations |
| 1 | Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. (Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC) Prostate 2019 May;79(7):701-708 28 Citations |
| 1 | RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. (Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X) Eur Urol 2019 Aug;76(2):157-166 25 Citations |
| 1 | FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis. (Seshacharyulu P, Rachagani S, Muniyan S, Siddiqui JA, Cruz E, Sharma S, Krishnan R, Killips BJ, Sheinin Y, Lele SM, Smith LM, Talmon GA, Ponnusamy MP, Datta K, Batra SK) Oncogene 2019 Jun;38(26):5265-5280 51 Citations |
| 1 | Immediate versus delayed prostatectomy and the fate of patients who progress to a higher risk disease on active surveillance. (Mallya A, Senguttuvan-Karthikeyan V, Sivaraman A, Barret E, Galiano M, Cathala N, Mombet A, Prapotnich D, Sanchez-Salas R, Cathelineau X) Actas Urol Esp (Engl Ed) 2019;43(6):324-330 1 Citation |
| 1 | Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. (Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M 3rd, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM) Int J Radiat Oncol Biol Phys 2019 Aug 01;104(5):1057-1065 13 Citations |
| 1 | Comprehensive Evaluation of Focal Therapy Complications in Prostate Cancer: A Standardized Methodology. (Bakavicius A, Sanchez-Salas R, Muttin F, Sivaraman A, Dell'Oglio P, Barret E, Rozet F, Mombet A, Prapotnich D, Cathala N, Cathelineau X) J Endourol 2019 Jul;33(7):509-515 25 Citations |
| 1 | Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. (Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, Low DA, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Gore EM, Albert M, Pisansky TM, Faria SL, Chen Y, Koontz BF, Swanson GP, Pugh SL, Sandler HM) Radiother Oncol 2019 Jun;135:19-24 24 Citations |
| 1 | Re: Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate. (Siegel C) J Urol 2019 Aug;202(2):190 |
| 2 | Classification before segmentation: Improved u-net prostate segmentation (Nowling RJ, Bukowy J, McGarry SD, Nencka AS, Blasko O, Urbain J, Lowman A, Barrington A, Banerjee A, Iczkowski KA, Laviolette PS) 2019 IEEE EMBS International Conference on Biomedical and Health Informatics Bhi 2019 Proceedings May 2019 12 Citations |
| 1 | Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. (Krook MA, Barker H, Chen HZ, Reeser JW, Wing MR, Martin D, Smith AM, Dao T, Bonneville R, Samorodnitsky E, Miya J, Freud AG, Monk JP, Clinton SK, Roychowdhury S) Prostate Cancer Prostatic Dis 2019 Dec;22(4):624-632 7 Citations |
| 1 | Genomic correlates of clinical outcome in advanced prostate cancer. (Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL) Proc Natl Acad Sci U S A 2019 Jun 04;116(23):11428-11436 1107 Citations |
| 1 | Cascading Classifiers Improve Prostate Segmentation (Nowling, Ronald Bukowy, John McGarry, Sean Nencka, Andrew Urbain, Jay Lowman, Allison Barrington, Alexandar Hohenwalter, Mark Banerjee, Anjishnu Iczkowski, Kenneth LaViolette, Peter ) Proc. ISMRM (2019): 4035 |
| 1 | Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. (Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G, Bentzen SM, Janelsins M, Elliott RM, Pharoah PDP, Burnet NG, Dearnaley DP, Gulliford SL, Hall E, Sydes MR, Aguado-Barrera ME, Gómez-Caamaño A, Carballo AM, Peleteiro P, Lobato-Busto R, Stock R, Stone NN, Ostrer H, Usmani N, Singhal S, Tsuji H, Imai T, Saito S, Eeles R, DeRuyck K, Parliament M, Dunning AM, Vega A, Rosenstein BS, West CML) J Natl Cancer Inst 2020 Feb 01;112(2):179-190 95 Citations |
| 1 | Exposure to an Environmentally Relevant Phthalate Mixture During Prostate Development Induces MicroRNA Upregulation and Transcriptome Modulation in Rats. (Scarano WR, Bedrat A, Alonso-Costa LG, Aquino AM, Fantinatti BEA, Justulin LA, Barbisan LF, Freire PP, Flaws JA, Lemos B) Toxicol Sci 2019 Sep 01;171(1):84-97 56 Citations |
| 1 | Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression. (Bowen C, Ostrowski MC, Leone G, Gelmann EP) Cancer Res 2019 Aug 15;79(16):4124-4134 31 Citations |
| 1 | Genetic associations of breast and prostate cancer are enriched for regulatory elements identified in disease-related tissues. (Chen H, Kichaev G, Bien SA, MacDonald JW, Wang L, Bammler TK, Auer P, Pasaniuc B, Lindström S) Hum Genet 2019 Oct;138(10):1091-1104 7 Citations |
| 4 | Serial T2-Weighted Magnetic Resonance Images Acquired on a 1.5 Tesla Magnetic Resonance Linear Accelerator Reveal Radiomic Feature Variation in Organs at Risk: An Exploratory Analysis of Novel Metrics of Tissue Response in Prostate Cancer. (Lorenz JW, Schott D, Rein L, Mostafaei F, Noid G, Lawton C, Bedi M, Li XA, Schultz CJ, Paulson E, Hall WA) Cureus 2019 Apr 20;11(4):e4510 |
| 2 | Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. (Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, Kallajoki MA, See WA, Rannikko A, Mirtti T, Nevalainen MT) Cancer Epidemiol Biomarkers Prev 2019 Oct;28(10):1642-1651 10 Citations |
| 4 | Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review. (Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Wickle JD, Lawton CA, Hall WA) J Natl Compr Canc Netw 2019 Jul 01;17(7):829-837 15 Citations |
| 1 | Thirty-day hospital revisits after prostate brachytherapy: who is at risk? (Li B, Kirshenbaum EJ, Blackwell RH, Gange WS, Saluk J, Zapf MAC, Kothari AN, Flanigan RC, Gupta GN) Prostate Int 2019 Jun;7(2):68-72 5 Citations |
| 3 | Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. (Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT) Mol Cancer Ther 2020 Jan;19(1):231-246 22 Citations |
| 5 | Exploring health behaviors, quality of life, and support needs in African-American prostate cancer survivors: a pilot study to support future interventions. (Stolley MR, Sheean P, Matthews L, Banerjee A, Visotcky A, Papanek P, Woodley L, Flynn KE) Support Care Cancer 2020 Jul;28(7):3135-3143 12 Citations |
| 1 | Opportunities and Challenges of Genomically Guided Decision Making for Patients With Prostate Cancer. (Hall WA) Pract Radiat Oncol 2020;10(2):93-94 |
| 1 | Prostate Cancer (Michalski JM, Pisansky TM, Lawton CA, Potters L) Gunderson and Tepper S Clinical Radiation Oncology 1 January 2020:1054-1114.e22 1 Citation |
| 1 | Development and validation of a genomic tool to predict seminal vesicle invasion in adenocarcinoma of the prostate (Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, Tosoian JJ, Morgan TM, Mehra R, Salami SS, Nguyen PL, Lawton CAF, Spratt DE, Feng F) JCO Precision Oncology 2020;4:1228-1238 4 Citations |
| 1 | A Prospective Multi-Institutional Phase I/II Trial of Step-Wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer. (Ritter MA, Kupelian PA, Petereit DG, Lawton CA, Anger N, Geye H, Chappell RJ, Forman JD) Pract Radiat Oncol 2020;10(5):345-353 5 Citations |
| 1 | Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. (Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L, Kohli M) Prostate Cancer Prostatic Dis 2020 Dec;23(4):705-713 21 Citations |
| 1 | Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. (Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE) JAMA Oncol 2020 May 01;6(5):735-743 92 Citations |
| 1 | Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. (Kmak JA, Agarwal N, He Y, Heilmann AM, Miller VA, Ross JS, Pal SK, Ali SM, Kilari D) Case Rep Oncol 2020;13(1):456-461 4 Citations |
| 1 | Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. (Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS) Cell Rep 2020 May 26;31(8):107669 220 Citations |
| 1 | FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer. (Kichloo A, Amir R, Aljadah M, Wani F, Solanki S, Singh J, Chugh SS) J Investig Med High Impact Case Rep 2020;8:2324709620941313 7 Citations |
| 1 | CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. (Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A) JCO Precis Oncol 2020;4:382-392 |
| 3 | NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. (Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF) Int J Radiat Oncol Biol Phys 2021 Jan 01;109(1):174-185 135 Citations |
| 6 | Radio-pathomic mapping model generated using annotations from five pathologists reliably distinguishes high-grade prostate cancer. (McGarry SD, Bukowy JD, Iczkowski KA, Lowman AK, Brehler M, Bobholz S, Nencka A, Barrington A, Jacobsohn K, Unteriner J, Duvnjak P, Griffin M, Hohenwalter M, Keuter T, Huang W, Antic T, Paner G, Palangmonthip W, Banerjee A, LaViolette PS) J Med Imaging (Bellingham) 2020 Sep;7(5):054501 16 Citations |
| 5 | Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural network. (Bukowy JD, Foss H, McGarry SD, Lowman AK, Hurrell SL, Iczkowski KA, Banerjee A, Bobholz SA, Barrington A, Dayton A, Unteriner J, Jacobsohn K, See WA, Nevalainen MT, Nencka AS, Ethridge T, Jarrard DF, LaViolette PS) J Med Imaging (Bellingham) 2020 Sep;7(5):057501 9 Citations |
| 1 | Survey of Radiation Oncologists to Assess Interest and Potential Use of a Genetic Test Predicting Susceptibility for the Development of Toxicities After Prostate Cancer Radiation Therapy. (Collado K, Kerns SL, Diefenbach MA, Peterson-Roth E, Koski R, Ostrer H, Stock RG, Mattessich M, Kaplan P, Rosenstein BS) Adv Radiat Oncol 2020;5(5):897-904 2 Citations |
| 2 | Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. (Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, Tosoian JJ, Morgan TM, Mehra R, Salami SS, Nguyen PL, Lawton CAF, Spratt DE, Feng F) JCO Precis Oncol 2020 Nov;4:1228-1238 4 Citations |
| 1 | A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. (Massi MC, Gasperoni F, Ieva F, Paganoni AM, Zunino P, Manzoni A, Franco NR, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Symonds PR, Johnson K, Lambrecht M, Haustermans K, De Meerleer G, de Ruysscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Avuzzi B, Giandini T, Valdagni R, Cicchetti A, Azria D, Jacquet MF, Rosenstein BS, Stock RG, Collado K, Vega A, Aguado-Barrera ME, Calvo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T) Front Oncol 2020;10:541281 32 Citations |
| 1 | Early Comparative Toxicity Outcomes of Patients With Prostate Cancer Receiving Initial Cryotherapy and Radiotherapy Salvage. (Jiang C, Godette K, Hall WA, Bennett JK, Rossi P, Cooper S, Jani AB, Patel PR) Clin Genitourin Cancer 2021 Jun;19(3):267-270.e1 3 Citations |
| 1 | Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. (DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK) Clin Cancer Res 2021 Feb 01;27(3):759-774 76 Citations |
| 2 | Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. (Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT) Cancers (Basel) 2020 Nov 18;12(11) 9 Citations |
| 1 | Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer. (Heninger E, Sethakorn N, Kosoff D, Hematti P, Kuczler MD, Pienta KJ, Lang JM) Oncotarget 2020 Nov 17;11(46):4253-4265 5 Citations |
| 1 | Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. (Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M 3rd, Sun Y, Lawton CAF) J Clin Oncol 2021 Jan 10;39(2):136-144 72 Citations |
| 1 | Co-registration tool for large format whole mount prostate multi-plex histology (Brehler M, Lowman AK, Bobholz S, McGarry SD, Banerjee A, Iczkowski K, Laviolette PS) Progress in Biomedical Optics and Imaging Proceedings of SPIE 2021;11603 |
| 1 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. (Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokołorczyk D, Lubiński J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczek B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA) Nat Genet 2021 Jan;53(1):65-75 372 Citations |
| 1 | Pain management following robotic-assisted radical prostatectomy: transitioning to an opioid free regimen. (Prebay ZJ, Medairos R, Landowski T, Everett RG, Doolittle J, Kansal JK, Jacobsohn K, Johnson SC) J Robot Surg 2021 Dec;15(6):923-928 7 Citations |
| 1 | Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. (Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R) Oncologist 2021 Apr;26(4):e715-e718 8 Citations |
| 1 | Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. (Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT) JAMA Oncol 2021 Apr 01;7(4):544-552 133 Citations |
| 1 | Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer. (Chesnut GT, Tin AL, Sivaraman A, Takeda T, Lee T, Fainberg J, Benfante N, Sjoberg DD, Vargas HA, Fine SW, Scardino PT, Eastham JA, Coleman JA, Touijer KA, Zelefsky MJ, Ehdaie B) Urol Oncol 2021 Aug;39(8):495.e17-495.e24 4 Citations |
| 1 | Factors influencing treatment of veterans with advanced prostate cancer. (Caram MEV, Burns J, Kumbier K, Sparks JB, Tsao PA, Chapman CH, Bauman J, Hollenbeck BK, Shahinian VB, Skolarus TA) Cancer 2021 Jul 01;127(13):2311-2318 10 Citations |
| 1 | Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. (Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML) Nat Commun 2021 Mar 30;12(1):1979 129 Citations |
| 9 | Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. (Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF) Pract Radiat Oncol 2021;11(6):527-533 6 Citations |
| 1 | Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. (Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS) J Clin Invest 2021 May 17;131(10) 40 Citations |
| 1 | Early Comparative Toxicity Outcomes of Patients With Prostate Cancer Receiving Initial Cryotherapy and Radiotherapy Salvage (Jiang C, Godette K, Hall WA, Bennett JK, Rossi P, Cooper S, Jani AB, Patel PR) Clinical Genitourinary Cancer June 2021;19(3):267-270.e1 3 Citations |
| 1 | Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. (Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B) JAMA Oncol 2021 Jun 04;7(9):1-5 68 Citations |
| 1 | Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. (Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS) J Clin Invest 2021 Jun 15;131(12) |
| 1 | Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. (Kowalczyk KJ, Madi RH, Eden CG, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi AM, Hwang J, Kim IY, Hu JC) J Urol 2021 Nov;206(5):1184-1191 27 Citations |
| 2 | The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy. (Prebay ZJ, Medairos R, Doolittle J, Langenstroer P, Jacobsohn K, See WA, Johnson SC) Prostate 2021 Oct;81(14):1064-1070 12 Citations |
| 1 | PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. (Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R) Prostate Cancer Prostatic Dis 2022 Sep;25(3):388-396 28 Citations |
| 1 | Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. (Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M 3rd, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU) Int J Radiat Oncol Biol Phys 2022 Feb 01;112(2):294-303 33 Citations |
| 1 | Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. (Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH) Prostate 2021 Dec;81(16):1382-1389 14 Citations |
| 1 | Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation. (Yun Ooi K, Pereira I, Nagar H, Simcock R, Katz MS, Parker CC, Lawton C, Saeed H) Clin Transl Radiat Oncol 2021 Nov;31:21-27 |
| 1 | Second-generation jak2 inhibitors for advanced prostate cancer: Are we ready for clinical development? (Beinhoff P, Sabharwal L, Udhane V, Maranto C, Laviolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT) Cancers October-2 2021;13(20) 23 Citations |
| 3 | Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development? (Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT) Cancers (Basel) 2021 Oct 17;13(20) 23 Citations |
| 1 | Real-Time Motion Tracking and Correction During Tomotherapy for Prostate Cancer: Impact of Fiducial Migration. (Chen GP, Tai A, Omari EA, Bedi M, Lawton CAF, Li A) Int J Radiat Oncol Biol Phys 2021 Nov 01;111(3S):e539-e540 |
| 1 | Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial (B. Movsas, J. Rodgers, M. A. Elshaikh, A. A. Martinez, G. Morton, D. J. Krauss, D. Yan, D. E. Citrin, B. Hershatter, J. M. Michalski, R. J. Ellis III, V. S. Kavadi, E. M. Gore, G. S. Gustafson, C. A. Schulz, V. Velker, A. C. Olson, T. G. Karrison, H. M. Sandler, D. W. Bruner) International Journal of Radiation Oncology Biology Physics B. Movsas, J. Rodgers, M.A. Elshaikh, A.A. Martinez, G. Morton, D.J. Krauss, D. Yan, D.E. Citrin, B. Hershatter, J.M. Michalski, R.J. Ellis, V.S. Kavadi, E.M. Gore, G.S. Gustafson, C.A. Schulz, V. Velker, A.C. Olson, T.G. Karrison, H.M. Sandler, D.W. Bruner, Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial, International |
| 7 | Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness. (McGarry SD, Brehler M, Bukowy JD, Lowman AK, Bobholz SA, Duenweg SR, Banerjee A, Hurrell SL, Malyarenko D, Chenevert TL, Cao Y, Li Y, You D, Fedorov A, Bell LC, Quarles CC, Prah MA, Schmainda KM, Taouli B, LoCastro E, Mazaheri Y, Shukla-Dave A, Yankeelov TE, Hormuth DA 2nd, Madhuranthakam AJ, Hulsey K, Li K, Huang W, Huang W, Muzi M, Jacobs MA, Solaiyappan M, Hectors S, Antic T, Paner GP, Palangmonthip W, Jacobsohn K, Hohenwalter M, Duvnjak P, Griffin M, See W, Nevalainen MT, Iczkowski KA, LaViolette PS) J Magn Reson Imaging 2022 Jun;55(6):1745-1758 13 Citations |
| 1 | The impeded diffusion fraction quantitative imaging assay demonstrated in multi-exponential diffusion phantom and prostate cancer. (Malyarenko DI, Swanson SD, McGarry SD, LaViolette PS, Chenevert TL) Magn Reson Med 2022 Apr;87(4):2053-2062 4 Citations |
| 1 | Histological validation of prostate tissue composition measurement using hybrid multi-dimensional MRI: agreement with pathologists' measures. (Chatterjee A, Antic T, Gallan AJ, Paner GP, Lin LI, Karczmar GS, Oto A) Abdom Radiol (NY) 2022 Feb;47(2):801-813 12 Citations |
| 1 | Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. (De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS) JCI Insight 2021 Dec 08;6(23) 23 Citations |
| 1 | Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. (Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, Souhami L, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B) Int J Radiat Oncol Biol Phys 2022 Jan 01;112(1):83-92 14 Citations |
| 1 | Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126 (Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, Souhami L, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B) International Journal of Radiation Oncology Biology Physics 1 January 2022;112(1):83-92 14 Citations |
| 2 | Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. (Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, Bylund K, Rosenzweig D, Hall W, De Ruyck K, Rosenstein BS, Stock RG, Gómez-Caamaño A, Vega A, Sosa-Fajardo P, Taboada-Valladares B, Aguado-Barrera ME, Parker C, Veldeman L, Fonteyne V, Bultijnck R, Talbot CJ, Symonds RP, Johnson K, Rattay T, Webb A, Lambrecht M, de Ruysscher D, Vanneste B, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Rancati T, Avuzzi B, Valdagni R, Azria D, Farcy Jacquet MP, Chang-Claude J, Seibold P, West C, Janelsins M, Chen Y, Messing E, Morrow G, REQUITE Consortium) Radiother Oncol 2022 Mar;168:75-82 18 Citations |
| 1 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators) N Engl J Med 2022 Mar 24;386(12):1132-1142 881 Citations |
| 5 | Diffusion Restriction Comparison between Gleason 4 Fused Glands and Cribriform Glands within Patient Using Whole-Mount Prostate Pathology as Ground Truth. (Duenweg SR, Fang X, Bobholz SA, Lowman AK, Brehler M, Kyereme F, Iczkowski KA, Jacobsohn KM, Banerjee A, LaViolette PS) Tomography 2022 Mar 02;8(2):635-643 4 Citations |
| 1 | Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer. (Coleman IM, DeSarkar N, Morrissey C, Xin L, Roudier MP, Sayar E, Li D, Corey E, Haffner MC, Nelson PS) Clin Cancer Res 2022 Jul 15;28(14):3127-3140 38 Citations |
| 1 | ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer. (Bittner NHJ, Cox BW, Davis B, King M, Lawton CAF, Merrick GS, Orio P, Ouhib Z, Rossi P, Showalter T, Small W Jr, Schechter NR) Am J Clin Oncol 2022 Jun 01;45(6):249-257 5 Citations |
| 3 | The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. (Hall WA, Karrison TG, Rosenthal SA, Amin MB, Gomella LG, Purdy JA, Sartor AO, Michalski JM, Garzotto MG, Bergom C, Jani AB, Lawton CAF, Simko JP, Moore JK, Gore EM, Lee WR, Nguyen PL, Danielson BL, Sandler HM, Feng FY) Int J Radiat Oncol Biol Phys 2022 Oct 01;114(2):266-274 4 Citations |
| 1 | Clinical Features and Body Composition in Men with Hormone-Sensitive Metastatic Prostate Cancer: A Pilot Study Examining Differences by Race. (Sheean PM, O'Connor P, Joyce C, Vasilopoulos V, Badami A, Stolley M) Prostate Cancer 2022;2022:9242243 9 Citations |
| 1 | Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. (Jackson WC, Tang M, Schipper MJ, Sandler HM, Zumsteg ZS, Efstathiou JA, Shipley WU, Seiferheld W, Lukka HR, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Hall WA, Dess RT, Lovett RD, Balogh AG, Feng FY, Spratt DE) J Clin Oncol 2022 Sep 20;40(27):3172-3179 28 Citations |
| 1 | Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. (Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV) Oncologist 2022 Oct 01;27(10):e783-e795 17 Citations |
| 3 | Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology. (Hall WA, Kishan AU, Hall E, Nagar H, Vesprini D, Paulson E, Van der Heide UA, Lawton CAF, Kerkmeijer LGW, Tree AC) Front Oncol 2022;12:962897 3 Citations |
| 1 | EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells. (d'Hose D, Mathieu B, Mignion L, Hardy M, Ouari O, Jordan BF, Sonveaux P, Gallez B) Molecules 2022 Sep 10;27(18) 7 Citations |
| 1 | Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study. (Hall WA, Shoag J, Spratt DE) Eur Urol 2022 Dec;82(6):661-662 2 Citations |
| 1 | Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis. (Shropshire DB, Acosta FM, Fang K, Benavides J, Sun LZ, Jin VX, Jiang JX) Front Med (Lausanne) 2022;9:965429 10 Citations |
| 1 | Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. (Huang J, Du M, Soupir A, Wang L, Tan W, Kalari KR, Kilari D, Park J, Huang CC, Kohli M, Wang L) Cancers (Basel) 2022 Sep 28;14(19) 6 Citations |
| 1 | Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes. (De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G) Cancer Discov 2023 Mar 01;13(3):632-653 60 Citations |
| 1 | Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study. (Heumann P, Aguado-Barrera ME, Avuzzi B, Azria D, Briers E, Bultijnck R, Choudhury A, De Ruysscher D, Farcy-Jacquet MP, Fonteyne V, Gómez Caamaño A, Helmbold I, Johnson K, Kerns SL, Lambrecht M, Lingard Z, Rancati T, Rosenstein BS, Sperk E, Paul Symonds R, Talbot C, Valdagni R, Vega A, Veldeman L, Ward T, Webb A, West CM, Chang-Claude J, Seibold P, REQUITE Consortium) Radiother Oncol 2023 Jan;178:109426 8 Citations |
| 1 | Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study (Hall WA, Shoag J, Spratt DE) European Urology December 2022;82(6):661-662 2 Citations |
| 1 | Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy. (Teunissen FR, Willigenburg T, Tree AC, Hall WA, Choi SL, Choudhury A, Christodouleas JP, de Boer JCJ, de Groot-van Breugel EN, Kerkmeijer LGW, Pos FJ, Schytte T, Vesprini D, Verkooijen HM, van der Voort van Zyp JRN) Pract Radiat Oncol 2023;13(3):e261-e269 43 Citations |
| 2 | Impact of Acetazolamide on Perioperative Pain Control in Robotic Assisted Laparoscopic Prostatectomy. (Medairos R, Lankford J, Everett R, Berger G, Weierstahl K, Woehlck H, Jacobsohn K, Johnson S) Urology 2023 Feb;172:126-130 |
| 2 | Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel. (Solanki AA, Puckett LL, Kujundzic K, Katsoulakis E, Park J, Kapoor R, Hagan M, Kelly M, Palta J, Ballas LK, DeMarco J, Hoffman KE, Lawton CAF, Michalski J, Potters L, Zelefsky M, Kudner R, Dawes S, Wilson E, Sandler H) Pract Radiat Oncol 2023;13(2):e149-e165 9 Citations |
| 2 | Confirming and Refining Our Existing Postoperative Treatment Strategies Through the Use of Novel Prostate-Specific Positron Emission Tomography (PET) Imaging. (Hall WA, Lawton CAF) Int J Radiat Oncol Biol Phys 2023 Jan 01;115(1):118-119 |
| 2 | Homologous point transformer for multi-modality prostate image registration. (Ruchti A, Neuwirth A, Lowman AK, Duenweg SR, LaViolette PS, Bukowy JD) PeerJ Comput Sci 2022;8:e1155 |
| 1 | Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. (Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh A, Montgomery B, Nelson PS, Yu EY) Prostate Cancer Prostatic Dis 2023 Mar;26(1):194-200 20 Citations |
| 1 | Neighborhood Deprivation and Rurality Associated with Patient-Reported Outcomes and Survival in Men with Prostate Cancer in NRG RTOG 0415 (Jinbing Bai, Stephanie L Pugh, Ronald Eldridge, Katherine A Yeager, Qi Zhang, W Robert Lee, Amit B Shah, Ian S Dayes, David P D'Souza, Jeff M Michalski, Jason A Efstathiou, John M Longo, Thomas M Pisansky, Jordan M Maier, Sergio L Faria, Anand B Desai, Samantha A Seaward, Howard M Sandler, Mary E Cooley, Deborah W Bruner ) Int J Radiation Oncology Biology Phys. Bai J, Pugh SL, Eldridge R, Yeager KA, Zhang Q, Lee WR, Shah AB, Dayes IS, D'Souza DP, Michalski JM, Efstathiou JA, Longo JM, Pisansky TM, Maier JM, Faria SL, Desai AB, Seaward SA, Sandler HM, Cooley ME, Bruner DW. Neighborhood Deprivation and Rurality Associated with Patient-Reported Outcomes and Survival in Men with Prostate Cancer in NRG RTOG 0415. Int J Radiat Oncol Biol Phys. 2023 Feb 1:S0360-3016(23)00082-2. doi: 10.1016/j.ijrobp.2023.01.035. Epub ahead of print. PMID: 36736921. |
| 1 | Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. (Lukka HR, Deshmukh S, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Feng FY, Pugh SL, Sandler HM, Kachnic LA) Int J Radiat Oncol Biol Phys 2023 Jul 15;116(4):770-778 11 Citations |
| 1 | Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. (Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, Tran P, Feng FY) Int J Radiat Oncol Biol Phys 2023 Jul 01;116(3):521-529 43 Citations |
| 1 | Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. (Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, Mishra MV, Roach M 3rd, Parliament MB, Choi KN, Pisansky TM, Husain SM, Malone SC, Horwitz EM, Feng F) Eur Urol 2024 Apr;85(4):373-381 10 Citations |
| 1 | Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. (Bai J, Pugh SL, Eldridge R, Yeager KA, Zhang Q, Lee WR, Shah AB, Dayes IS, D'Souza DP, Michalski JM, Efstathiou JA, Longo JM, Pisansky TM, Maier JM, Faria SL, Desai AB, Seaward SA, Sandler HM, Cooley ME, Bruner DW) Int J Radiat Oncol Biol Phys 2023 May 01;116(1):39-49 17 Citations |
| 4 | Comparison of a machine and deep learning model for automated tumor annotation on digitized whole slide prostate cancer histology. (Duenweg SR, Brehler M, Bobholz SA, Lowman AK, Winiarz A, Kyereme F, Nencka A, Iczkowski KA, LaViolette PS) PLoS One 2023;18(3):e0278084 8 Citations |
| 1 | Impact of intraoperative fluid restriction on renal outcomes in patients undergoing robotic-assisted laparoscopic prostatectomy. (Mori C, Iwasaki H, Sato I, Takahoko K, Inaba Y, Kawasaki Y, Tamaki G, Kakizaki H) J Robot Surg 2023 Oct;17(5):1989-1993 3 Citations |
| 1 | Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. (Movsas B, Rodgers JP, Elshaikh MA, Martinez AA, Morton GC, Krauss DJ, Yan D, Citrin DE, Hershatter BW, Michalski JM, Ellis RJ, Kavadi VS, Gore EM, Gustafson GS, Schulz CA, Velker VM, Olson AC, Cury FL, Papagikos MA, Karrison TG, Sandler HM, Bruner DW) J Clin Oncol 2023 Jun 10;41(17):3217-3224 15 Citations |
| 2 | Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. (Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY) Int J Radiat Oncol Biol Phys 2023 Oct 01;117(2):370-377 34 Citations |
| 1 | Predicting the germline dependence of hematuria risk in prostate cancer radiotherapy patients. (Oh JH, Lee S, Thor M, Rosenstein BS, Tannenbaum A, Kerns S, Deasy JO) Radiother Oncol 2023 Aug;185:109723 9 Citations |
| 1 | Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. (Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ, Focal Therapy Society) Eur Urol 2023 Dec;84(6):547-560 40 Citations |
| 3 | Whole slide imaging (WSI) scanner differences influence optical and computed properties of digitized prostate cancer histology. (Duenweg SR, Bobholz SA, Lowman AK, Stebbins MA, Winiarz A, Nath B, Kyereme F, Iczkowski KA, LaViolette PS) J Pathol Inform 2023;14:100321 30 Citations |
| 1 | Current Trends in Chemotherapy in the Treatment of Metastatic Prostate
Cancer (Zhao J, Guercio BJ, Sahasrabudhe D.) Cancers |
| 1 | Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate Cancer. (Ordonez-Rubiano SC, Maschinot CA, Wang S, Sood S, Baracaldo-Lancheros LF, Strohmier BP, McQuade AJ, Smith BC, Dykhuizen EC) J Med Chem 2023 Aug 24;66(16):11250-11270 12 Citations |
| 1 | Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration. (Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A) Res Sq 2023 Aug 10 |
| 2 | Development of Prostate Bed Delineation Consensus Guidelines for Magnetic Resonance Image-Guided Radiotherapy and Assessment of Its Effect on Interobserver Variability. (Sritharan K, Akhiat H, Cahill D, Choi S, Choudhury A, Chung P, Diaz J, Dysager L, Hall W, Huddart R, Kerkmeijer LGW, Lawton C, Mohajer J, Murray J, Nyborg CJ, Pos FJ, Rigo M, Schytte T, Sidhom M, Sohaib A, Tan A, van der Voort van Zyp J, Vesprini D, Zelefsky MJ, Tree AC) Int J Radiat Oncol Biol Phys 2024 Feb 01;118(2):378-389 6 Citations |
| 1 | Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. (Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, Bolla M, Maingon P, de Reijke T, Joseph D, Ong WL, Sydes MR, Dearnaley DP, Tree AC, Carrier N, Nabid A, Souhami L, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Reiter RE, Rettig MB, Nickols NG, Steinberg ML, Valle LF, Ma TM, Farrell MJ, Neilsen BK, Juarez JE, Deng J, Vangala S, Avril N, Jia AY, Zaorsky NG, Sun Y, Spratt D, Kishan AU, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators) J Clin Oncol 2023 Nov 10;41(32):5005-5014 23 Citations |
| 1 | Prostate Adenocarcinoma Metastasis to the Rectal Submucosa and Mesorectal Lymph Node on 18 F-PSMA PET/CT. (Segal E, Dababo N, Bhalla D, Bucklan D) Clin Nucl Med 2023 Oct 01;48(10):e506-e508 3 Citations |
| 1 | Integrated transcriptome and proteome analysis indicates potential biomarkers of prostate cancer in offspring of pregnant rats exposed to a phthalate mixture during gestation and lactation. (Aquino AM, Alonso-Costa LG, Santos SAA, Rocha VA, Barbisan LF, Bedrat A, Justulin LA, Flaws JA, Lemos B, Scarano WR) Chemosphere 2023 Nov;341:140020 13 Citations |
| 1 | Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. (Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata PC) JAMA Netw Open 2023 Sep 05;6(9):e2334208 12 Citations |
| 3 | T2-Weighted MRI Radiomic Features Predict Prostate Cancer Presence and Eventual Biochemical Recurrence. (Duenweg SR, Bobholz SA, Barrett MJ, Lowman AK, Winiarz A, Nath B, Stebbins M, Bukowy J, Iczkowski KA, Jacobsohn KM, Vincent-Sheldon S, LaViolette PS) Cancers (Basel) 2023 Sep 06;15(18) 18 Citations |
| 1 | Quality of Life in Prostate Cancer Patients Undergoing Daily Adaptive Versus Non-Adaptive Radiation Therapy Utilizing A 1.5 Tesla MR-Linac (SE Beltran Ponce, LA Daamen, J Van der Voort vanZyp, JM Westerhoff, FJ Pos, JP Christodouleas, A Choudhury, U van der Heide, CAF Lawton, MW Straza, M Bedi, ES Paulson, HG Nasief, A Li, H Verkooijen, A Tree, WA Hall) International Journal of Radiation Oncology, Biology, Physics |
| 3 | Patient-Specific Deep Learning Auto-Segmentation for MR-Guided Adaptive Radiotherapy of Prostate Cancer. (Amjad A, Chen X, Hall WA, Lawton CAF, Li A, Paulson ES) Int J Radiat Oncol Biol Phys 2023 Oct 01;117(2S):e638-e639 |
| 4 | Quality of Life in Prostate Cancer Patients Undergoing Daily Adaptive Versus Non-Adaptive Radiation Therapy Utilizing A 1.5 Tesla MR-Linac. (Ponce SEB, Daamen LA, Van der Voort vanZyp J, Westerhoff JM, Pos FJ, Christodouleas JP, Choudhury A, van der Heide U, Lawton CAF, Straza MW Jr, Bedi M, Paulson ES, Nasief HG, Li A, Verkooijen H, Tree A, Hall WA) Int J Radiat Oncol Biol Phys 2023 Oct 01;117(2S):S114-S115 |
| 1 | Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer. (Phillips R, Proudfoot J, Davicioni E, Spratt DE, Feng FY, Simko J, Den RB, Pollack A, Rosenthal SA, Sartor O, Sweeney C, Attard G, Patel SI, Hall WA, Efstathiou JA, Shah AB, Hoffman KE, Pugh S, Sandler HM, Tran PT) Int J Radiat Oncol Biol Phys 2023 Oct 01;117(2S):S34-S35 |
| 1 | Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers. (Zhang A, Lau NA, Wong A, Brown LG, Coleman IM, De Sarkar N, Li D, DeLucia DC, Labrecque MP, Nguyen HM, Conner JL, Dumpit RF, True LD, Lin DW, Corey E, Alumkal JJ, Nelson PS, Morrissey C, Lee JK) Cancer Res Commun 2023 Nov 20;3(11):2358-2374 17 Citations |
| 3 | Quantitative Histomorphometric Features of Prostate Cancer Predict Patients Who Biochemically Recur Following Prostatectomy. (Duenweg SR, Brehler M, Lowman AK, Bobholz SA, Kyereme F, Winiarz A, Nath B, Iczkowski KA, Jacobsohn KM, LaViolette PS) Lab Invest 2023 Dec;103(12):100269 4 Citations |
| 1 | Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: A randomized clinical trial. (Sanchez-Salas R, Tourinho-Barbosa R, Sivaraman A, Borges RC, Candela L, Cathala N, Mombet A, Marra G, Sanchez LR, Boumezrag CB, Lanz C, Macek P, Korkes F, Cathelineau X) Prostate 2024 Feb;84(2):158-165 7 Citations |
| 2 | 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapies. (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L) medRxiv 2024 Oct 17 |
| 1 | Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. (Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Biobank Japan Project, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczek B, Schöttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas CM, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam AP, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell SM, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss MH, Loos RJF, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden SK, Easton DF, Ambs S, Edwards TL, Mägi R, Rebbeck TR, Fritsche L, Chanock SJ, Berndt SI, Wiklund F, Nakagawa H, Witte JS, Gaziano JM, Justice AC, Mancuso N, Terao C, Eeles RA, Kote-Jarai Z, Madduri RK, Conti DV, Haiman CA) Nat Genet 2023 Dec;55(12):2065-2074 116 Citations |
| 1 | The impact of margin reduction on radiation dose distribution of ultra-hypofractionated prostate radiotherapy utilizing a 1.5-T MR-Linac. (Onal C, Efe E, Bozca R, Yavas C, Yavas G, Arslan G) J Appl Clin Med Phys 2024 Jan;25(1):e14179 8 Citations |
| 1 | Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. (Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES) Eur Urol Oncol 2024 Aug;7(4):877-887 16 Citations |
| 1 | Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System. (Nguyen CB, Kobe C, Kumbier KE, Bauman J, Burns JA, Tsao PA, Sparks JB, Skolarus TA, Caram MEV) JCO Oncol Pract 2024 Jan;20(1):59-68 2 Citations |
| 1 | Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy. (Chatterjee A, Gallan A, Fan X, Medved M, Akurati P, Bourne RM, Antic T, Karczmar GS, Oto A) Cancers (Basel) 2023 Dec 13;15(24) 13 Citations |
| 1 | MRI-based Prostate Cancer Detection Using Cross-Shaped Windows Transformer (Li Y, Wynne J, Wang J, Qiu RLJ, Roper J, Pan S, Jani AB, Liu T, Patel PR, Mao H, Yang X) Progress in Biomedical Optics and Imaging Proceedings of SPIE 2024;12927 1 Citation |
| 1 | The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium (Yamamoto KL, Henderson N, Hwang C, Barata PC, Bilen MA, Kilari D, Graham L, Garje R, Rothstein S, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Schweizer MT, Armstrong AJ, Dorff TB, Alva AS, McKay RR) Journal of Clinical Oncology 2024;42(4) |
| 1 | Molecular and clinical correlates of high PSMA/FOLH1 mRNA expression in primary and metastatic prostate cancer (PC) (McKay RR, Nazari S, Elliott A, Rose BS, Barata PC, Kilari D, Garje R, Agarwal N, Nabhan C, Beltran H, Antonarakis ES, Bagrodia A) Journal of Clinical Oncology 2024;42(16) |
| 1 | Sexual health outcomes in sexual minority vs. heterosexual men after prostate radiotherapy (Dickstein DR, Kapouranis T, Flynn KE, Sigel KM, Nvepu E, Sheu RD, Stewart R, Wheldon C, O’Donnell R, Safer JD, Sfakianos JP, Galsky MD, Liu T, Rosser BRS, Rosenstein B, Jackson A, Lovelock M, Stock R, Goodman KA, Marshall DC) Journal of Clinical Oncology 2024;42(16) |
| 2 | A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC). (Kilari D, Kadambi SG, Baran AM, Zittel J, Burfeind JD, Messing EM, Van Veldhuizen PJ, Bylow KA, Sahasrabudhe DM, Mohile SG, Fung C) Journal of Clinical Oncology 2024;42(16_suppl):5089-5089 |
| 1 | Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy. (Lukka H, Pugh SL, Shipley WU, Major P, Sartor AO, Dayes IS, Bahary JP, Efstathiou JA, Pisansky TM, Zeitzer KL, Lawton CA, Dess RT, Camarata AS, Balogh AG, Souhami L, Rosenthal SA, Seiferheld W, Feng FY, Sandler HM) Journal of Clinical Oncology 2024;42(4):320-320 |
| 2 | Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB). (Bhatlapenumarthi V, De Sarkar N, Patwari A, Antonarakis ES, Nelson AA, Kilari D) Journal of Clinical Oncology 2024;42(4):206-206 1 Citation |
| 1 | PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). (Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group) J Clin Oncol 2024 Apr 01;42(10):1114-1123 43 Citations |
| 1 | Urinary Symptoms Change and Quality of Life After Robotic Radical Prostatectomy: A Secondary Analysis of a Randomized Controlled Trial. (Tourinho-Barbosa R, Sanchez-Salas R, Sivaraman A, Borges RC, Candela L, Batista LT, Cathala N, Mombet A, Marra G, Sanchez LR, Boumezrag CB, Lanz C, Macek P, Cathelineau X, Korkes F) Urology 2024 Mar;185:73-79 4 Citations |
| 1 | Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). (Beltran H, Dowlati A, Jain P, Johnson ML, Sanborn RE, Thompson JR, Mamdani H, Schenk EL, Aggarwal RR, Sankar K, Gramza AW, Anand BS, Choudhury NJ) Journal of Clinical Oncology February 2024;42:121-121 31 Citations |
| 1 | Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. (Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA) Eur Urol Focus 2024 Mar;10(2):271-278 3 Citations |
| 1 | MRI-based prostate cancer classification using 3D efficient capsule network. (Li Y, Wynne J, Wang J, Roper J, Chang CW, Patel AB, Shelton J, Liu T, Mao H, Yang X) Med Phys 2024 Jul;51(7):4748-4758 5 Citations |
| 4 | Examining the role of social relationships on health and health behaviors in African American men with prostate cancer: a qualitative analysis. (Awoyinka I, Tovar M, Young S, Beyer K, Kwarteng J, Knight J, Stolley M) Support Care Cancer 2024 Feb 21;32(3):178 2 Citations |
| 1 | Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. (Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T) Prostate Cancer Prostatic Dis 2025 Jun;28(2):378-384 15 Citations |
| 1 | Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling. (Maranto C, Sabharwal L, Udhane V, Pitzen SP, McCluskey B, Qi S, O'Connor C, Devi S, Johnson S, Jacobsohn K, Banerjee A, Iczkowski KA, Wang L, Dehm SM, Nevalainen MT) Sci Adv 2024 Mar;10(9):eadi2742 8 Citations |
| 3 | Morphologic features of prostate cancer-encased native vessels: An image analysis study. (Fernandez Gonzalez De La Vega C, Duenweg S, Jain P, Rubenstein SI, Bobholz S, Barrett MJ, LaViolette PS, Iczkowski KA) Pathol Res Pract 2024 Apr;256:155239 2 Citations |
| 1 | Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial. (Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CAF, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM) JAMA Oncol 2024 May 01;10(5):584-591 41 Citations |
| 1 | Necrotizing granulomatous epididymo-orchitis post intravesical BCG administration after brachytherapy for prostate cancer. (Jhaveri JK, Dahmen A, Lazarovich A, Nusbaum D, Trinh QD, Gupta N, Agarwal PK) Urol Case Rep 2024 May;54:102694 1 Citation |
| 1 | Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. (Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ) JCO Precis Oncol 2024 Apr;8:e2300567 22 Citations |
| 1 | Manzamine A reduces androgen receptor transcription and synthesis by blocking E2F8-DNA interactions and effectively inhibits prostate tumor growth in mice. (Karan D, Dubey S, Gunewardena S, Iczkowski KA, Singh M, Liu P, Poletti A, Choo YM, Chen HZ, Hamann MT) Mol Oncol 2024 Aug;18(8):1966-1979 6 Citations |
| 1 | MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study (Sritharan K, Daamen L, Pathmanathan A, Schytte T, Pos F, Choudhury A, van der Voort van Zyp JRN, Kerkmeijer LGW, Hall W, Hall E, Verkooijen HM, Herbert T, Hafeez S, Mitchell A, Tree AC) Clinical and Translational Radiation Oncology May 2024;46 11 Citations |
| 1 | Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. (Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza D, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Rodgers JP, Sandler HM) J Clin Oncol 2024 Jul 10;42(20):2377-2381 31 Citations |
| 1 | Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. (Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True LD, Sperger JM, Cheng HH, Yu EY, Montgomery RB, Hawley JE, Ha G, Persse T, Galipeau P, Lee JK, Harmon SA, Corey E, Lang JM, Sawyers CL, Morrissey C, Schweizer MT, Gulati R, Nelson PS, Haffner MC) NPJ Precis Oncol 2024 May 17;8(1):104 28 Citations |
| 1 | Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617. (Panian J, Henderson N, Barata PC, Bilen MA, Graham L, Heath EI, Herchenhorn D, Hwang C, Kilari D, Koshkin VS, Nauseef JT, Sokolova A, Zakharia Y, Schweizer MT, Dorff TB, Armstrong AJ, Alva AS, McKay RR) Journal of Clinical Oncology June 2024;42(16):5050-5050 2 Citations |
| 1 | Patient-Reported Outcomes Following Magnetic Resonance-Guided Radiation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. (Westerhoff JM, Lalmahomed TA, Meijers LTC, Henke L, Teunissen FR, Bruynzeel AME, Alongi F, Hall WA, Kishan AU, Intven MPW, Verkooijen HM, van der Voort van Zyp JRN, Daamen LA) Int J Radiat Oncol Biol Phys 2024 Sep 01;120(1):38-48 7 Citations |
| 1 | Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. (Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ) Prostate Cancer Prostatic Dis 2025 Jun;28(2):419-426 5 Citations |
| 1 | Target Volume Optimization for Localized Prostate Cancer. (Patel KR, van der Heide UA, Kerkmeijer LGW, Schoots IG, Turkbey B, Citrin DE, Hall WA) Pract Radiat Oncol 2024;14(6):522-540 5 Citations |
| 1 | Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. (Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES) Prostate Cancer Prostatic Dis 2025 Jun;28(2):411-418 16 Citations |
| 1 | Dosimetric evaluation of ultrafractionated dose escalation with simultaneous integrated boost to intraprostatic lesion using 1.5-Tesla MR-Linac in localized prostate cancer. (Onal C, Arslan G, Yavas C, Efe E, Yavas G) Rep Pract Oncol Radiother 2024;29(1):10-20 6 Citations |
| 1 | DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. (Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT) JCO Precis Oncol 2024 Aug;8:e2400014 7 Citations |
| 1 | Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer. (Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D) Clin Genitourin Cancer 2024 Dec;22(6):102187 |
| 1 | Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377. (Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY) Int J Radiat Oncol Biol Phys 2024 Dec 01;120(5):1461 |
| 1 | Prostate cancer and solid organ transplantation: patient management and outcomes. (Lazarovich A, Kristof TW, Steadman S, Dahmen AS, Josephson MA, Barth R, Morgan TM, Timsit MO, Eggener S) BJU Int 2025 Feb;135(2):339-345 3 Citations |
| 1 | 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. (Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY) medRxiv 2024 Oct 27 |
| 2 | Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials. (Patel KR, Nguyen PL, Proudfoot JA, Liu Y, Pra AD, Spratt DE, Pollack A, Sandler HM, Efstathiou JA, Lawton C, Simko JP, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Pugh SL, Davicioni E, Tran PT, Feng FY) Eur Urol Oncol 2026 Apr;9(2):413-421 2 Citations |
| 1 | Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer. (Huang F, Li K, Chen Z, Cui Z, Hankey W, Fang K, Yan J, Wang H, Jin VX, Dong Y, Wang Q) Oncogene 2025 Mar;44(8):481-493 6 Citations |
| 1 | Correlation of Prostate High-Resolution Microultrasound With Multiparametric Magnetic Resonance Imaging. (Pickersgill NA, Alkazemi MH, Ostergar A, Joseph K, Vetter JM, Barashi NS, Kim EH, Andriole GL, Sivaraman A) Urology 2025 Mar;197:33-39 2 Citations |
| 2 | Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer (Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D) Clinical Genitourinary Cancer December 2024;22(6) |
| 1 | A narrative clinical trials review in the realm of focal therapy for localized prostate cancer. (Lazarovich A, Viswanath V, Dahmen AS, Sidana A) Transl Cancer Res 2024 Nov 30;13(11):6529-6539 6 Citations |
| 1 | The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or TNM Staging. (Sridhar S, Abouelfetouh Z, Codreanu I, Gupta N, Zhang S, Efstathiou E, Karolyi DK, Shen SS, LaViolette PS, Miles B, Martin DR) Prostate 2025 Apr;85(5):413-423 3 Citations |
| 1 | Assessing the impact of a pre-processing pipeline on a tumor localization model in prostate MRI within a large multi-institutional dataset (NRGGU005) (Alley S, Tonneau M, Olivié D, Tempany-Afdhal CM, Choyke PL, Turkbey IB, van der Heide UA, Ellis RJ, Boike TP, Pennington JD, Frazier A, Lawton CAF, Leong N, Mihai AM, Morgan SC, Solanki AA, Michalski JM, Feng FY, Sandler H, Menard C, Kadoury S) Progress in Biomedical Optics and Imaging Proceedings of SPIE 2025;13410 |
| 1 | New rectum dose surface mapping methodology to identify rectal subregions associated with toxicities following prostate cancer radiotherapy (Bouzaki A, Green D, van Herk M, Shortall J, Puri T, Kerns S, Azria D, Farcy-Jacquet MP, Chang-Claude J, Choudhury A, Dunning A, Lambrecht M, Avuzzi B, Ruysscher DD, Seibold P, Sperk E, Talbot C, Vega A, Veldeman L, Webb A, Rosenstein B, West CM, Gioscio E, Rancati T, Osorio EV, McWilliam A) Physics and Imaging in Radiation Oncology January 2025;33 6 Citations |
| 4 | Measurement of Prostate Specific Antigen Testing Among Primary Care Patients in the United States, 2010-2019. (Ohnishi Y, Ganshert C, Kuriyama A, Davis-Maxwell A, Murphy MG, Demchuk C, Jackson JL) J Gen Intern Med 2025 Aug;40(11):2786-2788 |
| 2 | Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A 1H and 31P Magnetic Resonance Spectroscopy Study. (Orlovskiy S, Gupta PK, Arias-Mendoza F, Singh DK, Nova S, Nelson DS, Narayan V, Koch CJ, Hardy M, You M, Kalyanaraman B, Nath K) Int J Mol Sci 2025 Jan 09;26(2) |
| 1 | Stress testing deep learning models for prostate cancer detection on biopsies and surgical specimens (Flannery BT, Sandler HM, Lal P, Feldman MD, Santa-Rosario JC, Pathak T, Mirtti T, Farre X, Correa R, Chafe S, Shah A, Efstathiou JA, Hoffman K, Hallman MA, Straza M, Jordan R, Pugh SL, Feng F, Madabhushi A) Journal of Pathology February 2025;265(2):146-157 5 Citations |
| 1 | Maximum Surgical Resection Followed by Radiation Therapy for the Management of Mucinous Adenocarcinoma of the Prostate. (Patel KR, Hall WA) Int J Radiat Oncol Biol Phys 2025 Mar 01;121(3):582 |
| 1 | Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. (Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT) Eur Urol Oncol 2026 Apr;9(2):430-437 3 Citations |
| 1 | Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials. (Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, Hayoz S, Michalski JM, Spratt DE, Liu Y, Schär C, Berlin AM, Zwahlen DR, Simko JP, Hölscher T, Efstathiou JA, Polat B, Sandler HM, Hildebrandt G, Parliament MB, Mueller AC, Dayes IS, Plasswilm L, Correa RJM, Robertson JM, Karrison TG, Davicioni E, Hall WA, Feng FY, Pollack A, Thalmann GN, Nguyen PL, Aebersold DM, Tran PT, Zhao SG) Ann Oncol 2025 May;36(5):572-582 14 Citations |
| 2 | Comparison of intensity normalization methods in prostate, brain, and breast cancer multi-parametric magnetic resonance imaging. (Duenweg SR, Bobholz SA, Lowman AK, Winiarz A, Nath B, Barrett MJ, Kyereme F, Vincent-Sheldon S, LaViolette P) Front Oncol 2025;15:1433444 4 Citations |
| 4 | A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer. (Farazi M, Yang X, Gehl CJ, Barnett GC, Burnet NG, Chang-Claude J, Parker CC, Dunning AM, Azria D, Choudhury A, Rancati T, De Ruysscher D, Seibold P, Sperk E, Talbot CJ, Veldeman L, Webb AJ, Elliott R, Aguado-Barrera ME, Carballo AM, Fuentes-Ríos O, Gómez-Caamaño A, Peleteiro P, Vega A, Ostrer H, Rosenstein BS, Saito S, Parliament M, Usmani N, Marples B, Chen Y, Morrow G, Messing E, Janelsins MC, Hall W, West CML, Auer PL, Kerns SL) Cancer Epidemiol Biomarkers Prev 2025 May 02;34(5):795-804 4 Citations |
| 2 | 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies. (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L) Commun Med (Lond) 2025 Mar 04;5(1):61 6 Citations |
| 1 | Sexual Health Outcomes in Sexual Minority and Heterosexual Men After Prostate Radiation Therapy. (Dickstein DR, Kapouranis T, Sigel K, Wheldon CW, Nvepu E, Javier NM, Stewart R, Galsky M, Sfakianos J, Safer JD, Stock R, Goodman K, Rosser BRS, Flynn KE, Marshall DC) Int J Radiat Oncol Biol Phys 2025 Jun 01;122(2):416-423 3 Citations |
| 2 | Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers 2020, 12, 3412. (Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT) Cancers (Basel) 2025 Mar 10;17(6) |
| 1 | Contemporary neighborhood redlining and racial mortgage lending bias and disparities in prostate cancer survival. (Lawrence WR, Freedman ND, McGee-Avila JK, Hong HG, Gomez SL, Loehrer AP, Beyer KMM, Zhou Y, Magnani JW, Neighbors HW, Johnson JA, Lin Z, Davidoff AJ, Llanos AAM, Shiels MS) Cancer 2025 Apr 15;131(8):e35850 5 Citations |
| 1 | Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials. (Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL) J Clin Oncol 2025 Nov 10;43(32):3494-3504 24 Citations |
| 1 | 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. (Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY) Front Oncol 2025;15:1541878 2 Citations |
| 1 | Corrigendum to "RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression" [Eur. Urol. 76(2) (2019) 157-166]. (Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X) Eur Urol 2025 Jul;88(1):121 |
| 1 | SCORT-Cas13d Nanotherapy Precisely Targets the 'Undruggable' Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo. (Cui Z, Huang F, Fang K, Yan J, Zhang Y, Kang DD, Zhou Y, Zhao Y, Everitt JI, Hankey W, Armstrong AJ, Huang J, Wang H, Jin VX, Dong Y, Wang Q) Adv Sci (Weinh) 2025 Jun;12(23):e2417605 6 Citations |
| 1 | Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study. (Graff JN, Burotto M, Fong PC, Pook DW, Zurawski B, Manneh Kopp R, Salinas J, Bylow KA, Kramer G, Ratta R, Kwiatkowski M, Retz M, Kwak C, Arranz Arija JA, Gurney H, Matsubara N, Villanueva L, Todenhöfer T, Liang LW, Todoric J, Imai K, Stenzl A, KEYNOTE-641 Investigators) Ann Oncol 2025 Aug;36(8):976-987 17 Citations |
| 1 | Molecular and clinical characterization of KLK2 mRNA expression in prostate cancer (PC). (McKay RR, Nazari SS, Elliott A, Smith N, Barata PC, Kilari D, Rose BS, Garje R, Bagrodia A, Agarwal N, Antonarakis ES, Beltran H) Journal of Clinical Oncology June 2025;43:5050-5050 1 Citation |
| 1 | Dose-response mapping of bladder and rectum in prostate cancer patients undergoing radiotherapy with and without baseline toxicity correction (Puri T, Rancati T, Seibold P, Webb A, Osorio EV, Green A, Gioscio E, Azria D, Farcy-Jacquet MP, Chang-Claude J, Dunning A, Lambrecht M, Avuzzi B, de Ruysscher D, Sperk E, Vega A, Veldeman L, Rosenstein B, Shortall J, Kerns S, Talbot C, Morris AP, McWilliam A, Hoskin P, Choudhury A, West C, van Herk M) Physics and Imaging in Radiation Oncology July 2025;35 2 Citations |
| 1 | KDM3B Regulates Postradiation Fibrotic Responses in Prostate Stroma via N6-methyladenosine Modification of LOX. (Dong A, Sun X, Chen L, Tsai Y, Kerns S, Marples B, Xing D, Chen Y, Xie D, Sun Y) Int J Radiat Oncol Biol Phys 2025 Nov 15;123(4):1116-1131 1 Citation |
| 1 | Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial. (Phillips RM, Proudfoot JA, Davicioni E, Liu Y, Spratt DE, Simko JM, Den RB, Pollack A, Rosenthal SA, Sartor AO, Sweeney CJ, Attard G, Longoria L, Patel S, Straza MW, Efstathiou JA, Shah AB, Hoffman KE, Rodgers JP, Sandler HM, Feng FY, Tran PT) Eur Urol Oncol 2025 Aug;8(4):968-976 2 Citations |
| 1 | Extracellular vesicle proteomics identify neutrophils as potential mediators of bladder radiotoxicity in prostate cancer. (Molony RD, Akash MMH, Kerns SL, Marples B, Groves A, Dhinakaran C, Nichols LE, Lee YF) Cancer Lett 2025 Oct 28;631:217931 4 Citations |
| 1 | Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy. (Chan E, Pugh SL, Simko JP, Feng F, Shipley WU, Lukka HR, Bahary JP, Pisansky TM, Zeitzer KL, Gore E, Efstathiou JA, Rosenthal SA, Balogh AG, Lovett RD, Wong A, Dess RT, McGinnis LS, Kuettel M, DeMora L, Sandler HM) Prostate 2025 Oct;85(14):1315-1322 1 Citation |
| 1 | Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy. (Lukka HR, Pugh SL, Shipley WU, Major PP, Sartor O, Dayes IS, Bahary JP, Efstathiou JA, Pisansky TM, Zeitzer KL, Lawton CAF, Dess RT, Camarata AS, Balogh AG, Souhami L, Rosenthal SA, Pennington JD, Seiferheld WF, Feng FY, Sandler HM) Int J Radiat Oncol Biol Phys 2025 Nov 15;123(4):990-999 6 Citations |
| 1 | Daily Online Adaptive Recontouring with 1.5 T MR-Guided Radiotherapy Improves Urinary Symptoms in Prostate Cancer: an R-IDEAL stage 2b Analysis From the MOMENTUM Study (William Hall; Faye Raaijmakers; Alison Tree; John Christodouleas; Sara Beltran Ponce; Thomas Matoska; Jochem Voort Van Zyp; Jasmijn Westerhoff; Uulke Van Der Heide; Floris J Pos; Paulien Westhoff; Ananya Choudhury; Danny Vesprini; Shaista Hafeez; Elgin Hoffmann; Michael Straza; Paul Jeene; John M Longo; Clifton David Fuller; Filippo Alongi; Tine Schytte; Matthieu Bal; Hafid Akhiat; Juan Diaz; Nicolette O'Connell; Emma Hall; Lois Daamen; Helena Verkooijen) The Lancet Oncology |
| 1 | Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence. (Ku AT, Shankavaram U, Trostel SY, Zhang H, Kartal S, Sater HA, Harmon SA, Carrabba NV, Liu Y, Ryu H, Proudfoot JA, Hong BH, Wood BJ, Pinto PA, Choyke PL, Roach M, Sandler HM, Pugh SL, Zeitzer KL, Mendez LC, Kapadia NS, Hall WA, Desai AB, Stoyanova RS, Pollack A, Davicioni E, Chua MLK, Turkbey B, Sowalsky AG, Citrin DE) Clin Cancer Res 2025 Dec 15;31(24):5211-5224 2 Citations |
| 1 | Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer. (McKay RR, Nazari SS, Elliott A, Ribeiro JR, Rose BS, Barata PC, Kilari D, Garje R, Agarwal N, Smith N, Antonarakis ES, Bagrodia A, Beltran H) Oncologist 2025 Nov 11;30(11) 1 Citation |
| 1 | Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005. (Alley S, Tonneau M, Olivié D, Tempany-Afdhal CM, Choyke PL, Turkbey IB, van der Heide UA, Ellis RJ, Kadoury S, Boike TP, Pennington JD, Frazier A, Lawton CAF, Leong N, Mihai AM, Morgan SC, Solanki AA, Michalski JM, Feng FY, Sandler HM, Menard C) J Magn Reson Imaging 2026 Feb;63(2):464-474 1 Citation |
| 1 | Integration of Dose Surface Maps and Genetic Data Identifies the Lower Posterior Rectum as a Key Region for Toxicity after Prostate Cancer Radiotherapy. (Bouzaki A, Vasquez Osorio E, Kerns S, van Herk M, Morris A, Shortall J, Azria D, Farcy-Jacquet MP, Chang-Claude J, Choudhury A, Dunning A, Lambrecht M, Avuzzi B, De Ruysscher D, Seibold P, Sperk E, Talbot C, Vega A, Veldeman L, Webb A, Rosenstein B, West C, Rancati T, Gioscio E, McWilliam A) Clin Cancer Res 2025 Dec 01;31(23):5006-5014 |
| 1 | Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617. (Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT, Raychaudhuri R, Reichert ZR, Dorff T, Armstrong AJ, Wang J, Alva A, McKay RR) Oncologist 2025 Nov 11;30(11) 2 Citations |
| 2 | Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis. (Zaorsky NG, Sun Y, Nabid A, Zapatero A, Bolla M, Joseph D, Maingon P, Guerrero A, Gonzalez AA, San-Segundo CG, Cabeza Rodríguez MÁ, Sole JM, Olivé AP, Steigler A, Souhami L, Carrier N, Armstrong JG, Gillham C, Pisansky TM, Schipper M, Sandler HM, Efstathiou JA, Lawton C, de Reijke TM, Attard G, Roy S, Morgan SC, Malone S, Hall WA, Nguyen PL, Shoag JE, Vince RA Jr, Calaway A, Garcia JA, Barata PC, Mendiratta P, Brown JR, Valle L, Rettig M, Dess RT, Jackson WC, Martin T, Jia AY, Steinberg M, Romero T, Kishan AU, Spratt DE) JAMA Oncol 2026 Jan 01;12(1):58-65 6 Citations |
| 3 | CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate Cancer. (Sharma K, Wilson DA, Wang Y, Haider S, Bhatlapenumarthi V, Boiarsky D, Cipriaso JM, Yermakov L, Dutta R, Vashisth M, Coleman IM, Bankhead A, Jadhav SK, Neupane B, Taylor BW, Morrissey C, Schweitzer MT, Montgomery RB, Rao S, Nevalainen MT, Nelson AA, Antonarakis ES, Pilié PG, Berchuk JE, Zarrabi KK, Pritchard CC, Kthari A, Chen HZ, George B, Kurzrock R, Ha G, Nelson PS, Auer PL, Banerjee A, Kilari D, De Sarkar N) bioRxiv 2025 Oct 14 |
| 1 | A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer. (Medina S, Tokuyama N, Hammouda K, Pathak T, Mirtti T, Fu P, Gupta S, Lal P, Sandler HM, Correa R, Chafe S, Shah A, Efstathiou JA, Hoffman K, Straza M, Hallman MA, Jordan R, Pugh SL, Sweeney CJ, Madabhushi A) Clin Cancer Res 2026 Feb 04;32(3):645-653 1 Citation |
| 1 | Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer. (Kilari D, Henderson NC, Yamamoto K, Yao Y, Hwang C, Barata PC, Bilen MA, Graham L, Garje R, Rothstein S, Haider S, Park JJ, Raychaudhuri R, Pilling A, Chin E, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Sokolova A, Ayanambakkam A, Zakharia Y, Schweizer MT, Armstrong AJ, Dorff TB, Reichert ZR, McKay RR) JCO Precis Oncol 2025 Dec;9:e2500590 1 Citation |
| 2 | Exploring Dietary Supplement Utilization Patterns Among African American Survivors of Prostate and Breast Cancer: A Cross-Sectional Analysis. (Kranjac CA, Sheean P, Banerjee A, Teng BQ, O'Connell K, Tovar M, Alonso E, Snider Z, Stolley M) Nutrients 2025 Nov 27;17(23) |
| 6 | Study design and methodologies for the men moving forward lifestyle intervention trial with black prostate cancer survivors. (Awoyinka I, Sheean P, Papanek P, Flynn KE, Bylow K, Kilari D, Gann P, Banerjee A, Stolley M) Contemp Clin Trials 2026 Feb;161:108205 |
| 9 | Radio-pathomic maps of histo-morphometric features trained with whole mount prostate histology distinguish prostate cancer on MP-MRI. (Duenweg SR, Bobholz SA, Lowman AK, Winiarz A, Nath B, Barrett MJ, Kyereme F, Vincent-Sheldon S, Bhatt K, Troy K, Kim M, Fair E, Iczkowski KA, Jacobsohn KM, Banerjee A, Hall WA, Nencka AS, LaViolette PS) medRxiv 2026 Jan 13 |
| 1 | Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD). (Guchhait K, Yoon HS, An HS, Shin S, Nam HS, Yanqui-Rivera FD, Oña SM, Mendez MÁ, Hwang JY, Park D, Park CS, Han JY, Chung DY, Park S, Kim EK, Yang SG, Cho SK) Oncogene 2026 Apr;45(14):1234-1246 |
| 1 | Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Repository. (Westley RL, Daamen LA, Teunissen FR, Vesprini D, Choudhury A, Pos FJ, Verkooijen HM, Fuller CD, Choi S, Hall WA, van der Voort van Zyp JRN, Christodouleas JP, Tree AC) Clin Oncol (R Coll Radiol) 2026 May;53:104074 |
| 1 | A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413. (Sayan M, Huang HC, Stewart EL, Showalter TN, Dicker AP, Grass GD, Gore EM, McDonald AM, Pennington JD, Hallman MA, Barani IJ, Hsu IC, Rooney M, Pugh SL, Nguyen PL, Tran PT, Roach Iii M) Cancers (Basel) 2026 Jun 18;18(12) |
